EUREKA Institute

International Certificate Program
April 3rd - 9th, 2016
Siracusa, Italy
The Three Pillars

The Eureka educational initiative is based on:

- an attitude of teamwork
- critical thinking skills
- knowledge of translational medicine

Eureka’s mission

The Institute’s mission is to develop a community of translational medicine professionals equipped to catalyze the application of discoveries for the benefit of human health. We do this by educating and building a community.

Overall Educational Objectives

Participants in the Certificate Program will:

1. Analyze the business, scientific and regulatory aspects of Translational Medicine (TM)
2. Explore the challenges professionals encounter in TM
3. Develop critical thinking skills to approach the challenges in Translational Medicine
4. Develop communication skills for presenting various topics to a broad spectrum of people
5. Analyze effective manuscript preparation and begin to apply the concepts to their own work

Educational Strategies

We use a number of educational strategies to achieve the overall course objectives and the goals of each individual activity. Key among these is creating an open and safe environment through which participants can navigate, and in which participants may interact.
Support

We thank the kind support of our partners: University Medical Center Utrecht, Singapore Health Services, Duke–NUS Medical School, University of Arizona, University of Miami, Stanford University Medical Centre, and sponsors; University College London, University of Arizona-Parent Project Muscular Dystrophy Program, Danone Center for Specialised Nutrition, Nature Medicine and Nature Medicine Biotechnology.

We deeply appreciate the Faculties for the 2016 International Certificate Program. They are generously donating their time and expertise to participate in the course. Our sincere gratitude goes to Julia Ong, who provides energy and cohesion to this Program. We want to recognize the dedicated effort and commitment of the Acute Frog Consulting team, Bob Chinello and Daria Pierotti. In addition, we thank our Artists-in-Residence Anna van Suchtelen and Brian Goeltzenleuchter for contributing their time and passion in cultivating the 2016 Translational Creativity program. Lastly, we thank Francesco Italia, Vittorio di Natale, and their colleagues at the Borgia del Casale for their extraordinary efforts, gastronomic artistry, and for the beautiful space in which the course is held. Eureka Board 2016: Salvo Albani, David Hafler, Janet Hafler, Berent Prakken, Norm Rosenblum, and Vicki Seyfert-Margolis.

Edited and compiled by The Eureka Institute for Translational Medicine

A publication of the Eureka Institute for Translational Medicine. Prepared in the partial fulfillment of the requirements for the certificate of completion. Continuing Medical Education credits are not being offered for this course, however the materials are in compliance with the requirements of the Accreditation Council for Continuing Medical Education. Course materials and handouts include edited and compiled works of multiple authors.

Reproduction of this document or any part thereof, or the additional materials offered throughout the course is governed by US copyright law (US Code, Title 17). Copying material contained in this document or other course materials for general distribution, for advertising or promotional purposes, for resale, for creating new collective works, or for commercial proprietary purposes, is strictly prohibited.

Requests for reprints or reproduction to:
Eureka Institute for Translational Medicine
c/o Ms Julia Ong
The Academia, Discovery Tower Level 8
20 College Road
Singapore 169856
info@eurekainstitute.org

© 2016 Eureka Institute for Translational Medicine
All Rights Reserved
About Translational Medicine

Today, the term “translational medicine” is a buzzword in biomedical sciences with a rapidly increasing number of meetings about it; courses on it; and institutes dedicated to it. A simple Pubmed search on “translational medicine” generates over 29,000 papers, while a Google search yields nearly 9,000,000 hits. Because of its popularity and its increased use, the meaning of the term translational medicine has become progressively ambiguous and is often used synonymously with clinical testing.

In our opinion, translational medicine encompasses the continuum of activities that extend from the conception of an idea all the way into Phase II/III clinical testing and, ultimately, the development of a tangible product. This itinerary includes multiple and diverse components requiring very different skills and competencies ranging from molecular medicine to pharmacology; from animal testing to clinical trial design; from intellectual property to venture capital.

Translational medicine is therefore the framework needed to ensure the evolution of novel technologies into tangible benefits for patients.

About the Program

You will find in the following pages:

- a brief introduction to Eureka and Translational Medicine
- basic logistical information
- course materials organized by day
- faculty, artists’ and participants’ bios

This is a living document that will grow and change with you as you move through the course. Because we focus on active participation rather than passive processes, the program will be tailored to your needs and expectations, both the ones pre-defined and those that arise in situ. The program materials are organized chronologically. For each session, you will find an abstract as well as its principal learning objectives.

Each day will start at 8:15 with coffee and brief social period, which will segue into the first session of the day (at 8.30 AM). “The course is balanced between didactic sessions, interactive discussion, and practical application. Please make opportunities to synthesize the discussions and explore, in a personal context, how the topics covered can be applied to your own work.

Evaluation of the course is an important part of reflecting on the experience and providing feedback aimed at course improvement. You will be provided with an e-based evaluation that can be completed on an ongoing basis throughout the course and should be submitted by the end of the course.”
Eureka Faculty Roster - April 2016

Salvatore Albani, MD, PhD,
Professor, Duke-NUS Medical School Singapore, Director, SingHealth Translational Immunology and Inflammation Centre, UCAN-A Chair

Sylvia Brugman, PhD,
Senior Postdoc, Cell Biology and Immunology group, Wageningen University; E-course developer, Eureka Institute

Roberto Chinello, MBA, BS,
Economics, Managing Partner, Acute Frog Consulting

Wainwright Fishburn, JD,
Partner, Cooley LLP

Patricia Furlong, RN, BS, MS,
Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy

Carol Gregorio, PhD, Luxford/Schoolcraft Professor, Professor and Head of Cellular and Molecular Medicine; Co-Director, Sarver Heart Center; Director, Molecular Cardiovascular Research Program.

Gianfranco Grompone, PhD, Engineer, Head of the Microbiota Unit and Scientific Officer at BIOASTER, France; Visiting Scientist at Institut Pasteur de Montevideo, Uruguay

David Hafler, MD, Chief and Chair of Neurology, Yale New Haven Hospital and Yale School of Medicine

Janet Hafler, EdD,
Professor of Pediatrics, Associate Dean for Educational Scholarship, Yale School of Medicine

Matthias von Herrath, MD,
Professor and Member with Tenure at the La Jolla Institute for Allergy and Immunology

Paul Krieg, PhD,
Professor of Cellular and Molecular Medicine, The University of Arizona

Kenneth A. Oye, BA, MA, PhD, Associate Professor of Political Science and Institute for Data Systems and Society and Director of the Program on Emerging Technologies (PoET), Massachusetts Institute Technology

Maria-Grazia Roncarolo, MD,
George D. Smith Professor of Pediatrics and Medicine Division Chief, Pediatric Stem Cell Transplantation and Regenerative Medicine Co-Director, Bass Center for Childhood Cancer and Blood Diseases Co-Director, Institute for Stem Cell Biology and Regenerative Medicine Department of Pediatrics Stanford School of Medicine

Kenneth A. Oye, BA, MA, PhD, Associate Professor of Political Science and Institute for Data Systems and Society and Director of the Program on Emerging Technologies (PoET), Massachusetts Institute Technology

Daria Pierotti, BSc, MSc, Cpsychol, Senior Consultant, Acute Frog Consulting, Partner

Berent Prakken, MD, PhD,
Professor of Pediatric Immunology, University Medical Centre Utrecht; Chair Research and Education Division Pediatrics, Co-Chair, UCAN-U;Chair, ENTRAIN

Sergio Quezada, PhD,
Professorial Research Fellow and Group Leader at UCL Cancer Institute and Head, Immune Regulation and Rumor Immunotherapy Laboratory

Norm Rosenblum, MD,
Professor of Pediatrics, Canada Research Chair in Developmental Nephrology, and Associate Dean, Physician Scientist Training, University of Toronto

Uri Tabori, MD, Staff Neuro Oncologist, Division of Haematology/Oncology, Associate Professor of Pediatrics, University of Toronto, Senior Scientist, Research Institute and The Arthur and Sonia Labatt Brain Tumour Research Centre The Hospital for Sick Children

Vicki Seyfert-Margolis, PhD,
CEO and Founder, My Own Med

Paul-Peter Tak, MD, PhD,
Professor of Medicine, Chief Immunology Officer and Senior Vice President R&D Pipeline, GlaxoSmithKline

Joris van Montfrans, MD,
Pediatrician – Immunologist, Division Pediatrics, Wilhelmina Children’s Hospital / UMC Utrecht, The Netherlands

- 5 -
Observer Faculty

Patrick J. Casey, PhD, Senior Vice Dean Research, Duke-NUS Medical School, James B. Duke Professor of Pharmacology and Cancer Biology, Duke University Medical Center

P.A.F.M. (Pieter) Doevendans MD PhD FESC, Head Department of Cardiology, Chairman and Medical Manager, Division Heart and Lungs, University Medical Center Utrecht

Nancy Sweitzer, MD, PhD, Director, Sarver Heart Center, Chief, Division of Cardiology, University of Arizona College of Medicine

Elaine Van der Put, PhD, MSPH, Chief Strategy Officer, University of Miami Miller School of Medicine, Chief of Strategic Operations, University of Miami Clinical and Translational Science Institute

Eureka Translational Creativity Faculty

Anna van Suchtelen, MA
Brian Goeltzenleuchter, MFA

Eureka 2016 Program Committee

Norm Rosenblum
Janet Hafler
Vicki Seyfert-Margolis
Salvo Albani

Introductory e-learning module for Translational Medicine

The Eureka course started with an online introduction prior to the face-to-face course in Siracusa in May since 2014 course. The course was developed by Eureka Faculty (coordinated by Juan Carlos Lopez and Sylvia Brugman), a 2010 Eureka alumnus together with Davey van de Heijden and Renee Filius (both at Elevate health). It was made possible thanks to generous support from EUTRAIN and the Child Health program of the UMC Utrecht.

Elevate Health is an online academy that educates international health professionals, elevating professional knowledge and improving health worldwide. This online e-learning course (e-course) aims to get everyone up to speed with regards to the definition and components of Translational Medicine before the participants arrive at the face-to-face course.
Sunday, April 3rd

Coffee
Time: 8:15 - 8:30

Introductions
Facilitator: Janet P. Hafler
Time: 8:30 - 10:00

Break, 10:00 - 10:15

Mapping Translational Medicine
Presenters: Berent Prakken and Salvatore Albani
Time: 10:15 - 11:30

Abstract
In this session, the objectives of the course and concepts of translational medicine will be introduced and defined.

Objectives
1. Define the field of translational medicine
2. Analyze the components involved
3. Discuss the challenges of translational medicine

Creativity and Science
Presenter: Berent Prakken and Gianfranco Grompone
Time: 11:30-12:00

Abstract
Most people would agree with the premise that creativity is at the center of scientific progress. However, incorporating creativity in science is remarkably challenging. In practice, often only little time and attention is consciously allocated for the creative processes in science. Instead time is taken up by many different practical tasks, such as the satisfying the rising number of regulatory and administrative requirements and answering an endless stream of e-mails. To counter this, a conscious action is needed; first of all to understand the process of creativity and, next, how it can be promoted in daily practice

Objectives
1. Rethink the importance of creativity as the basis of science
2. Understand the processes that promote and block creativity
3. Explore ways to foster creativity in real-life

Group Lunch, 12:00 - 13:30

Teaching and Learning: Team Building I
Presenter: Janet P. Hafler
Time: 13:30 - 14:30

Abstract
In this session the team building exercise will be discussed. The participants will begin to identify effective group member behaviors and one's role in a team, in addition to developing a network of colleagues.

Objectives
1. Define what constitutes a team
2. Discuss principles of effective group interaction
3. Discuss networks and their influence on career and science

“Sisyphus”, A Case Study
Facilitator: Norman Rosenblum
Written by: Salvatore Albani and Jessica Colomb
Time: 14:30 - 15:30

Abstract
“Sisyphus” is based on a real case about the development of a novel immunotherapeutic strategy. It focuses on compounds designed specifically for humans. Sisyphus addresses typical problems in proof-of-concept studies, development and regulation. This case also prevents incongruities in animal models of disease versus human application.

Objectives
1. Explore strategies for lead identification
2. Explore strategies for chemistry, manufacturing and controls (CMC) studies (funding and conduct)
3. Explore strategies for safety data in untraditional models

Break, 15:30 - 15:45

Mentoring Session I
Time: 15:45 - 16:45

Abstract and Goals
As part of the course, participants will present a dilemma they are currently facing to a small group of peers. This group will be mentored by faculty. Fellow course participants will act as a consultation group. The objective is to advance personal learning while practicing and improving approaches to, and organization of, problem solving. Reflections using practical real-world problems will anchor the concepts raised in the didactic portion of the program.
Sunday, April 3rd cont.

The Concept of druggability: Challenges and Opportunities
Presenter: Salvatore Albani and Sylvia Brugman Sylvia Brugman
Time: 16:15 - 17:15

Abstract
This conversation will address the general principles inspiring the “druggability” of a compound, technology or process. In other words, what are the key factors influencing the evolution of a scientific discovery or concept through the translational gradient to answer an unmet medical need. A lot of science is outstanding, but not all of it is “druggable”.

Objectives
1. Highlight the principles guiding movement from initial investigations into “advanced” studies
2. Discuss designing and managing clinical trials, including data management and interpretation
3. Explore the intersection of interests between key stakeholders (e.g. patients, regulators and business)

Sunday Social Program

Tour of the Borgia del Casale and Opening Dinner
20:00

Please join us to celebrate the 8th Annual International Certificate Program in Translational Medicine. Appetizers precede the dinner. Both will be served at the Borgia del Casale.
Monday, April 4th

Team Building II - off site
Facilitators: Daria Pierotti and Bob Chinello
Time: 09:00 - 14:30
(Pick up at 08:30 sharp in Piazza Archimede)

Logistical Note: Participants will meet in the Piazza Archimedes at 8:30 am EXACTLY on Monday morning. Buses will be waiting to transport participants to the faculty where the team building exercise is being held.

Abstract
The team building exercise will be led by Bob and Daria, of Acute Frog Consulting and will be comprised of a series of group activities to help the participants to make a better use of their teams by understanding team dynamics and the “social ingredients” of effective interaction.

Objectives:
1. Dig into some important issues related to “being in a team”
2. Develop self-awareness on how each participant works and plays a role within the team
3. Explore how teams can effectively function
4. Develop skills in self-awareness on how to improve personal effectiveness in working in a team

Introduction to Translational Creativity
Artists/Facilitators: Anna van Suchtelen and Brian Goeltzenleuchter
Time: 16:00 - 16:15

A Dose of Hope
Presenter: Patricia Furlong
Time: 16:45 - 17:45

Abstract
Patients and family members, when faced with a catastrophic diagnosis (rare or otherwise) feel isolated and alone. The dreams and plans for the life they imagined are gone. Parents with sick children feel as if they have failed parenthood, no longer able to ‘fix’ things or dry every tear. They have few choices and by default, become an advocate. They search the internet, sign up for Google alerts, connect on FB and Twitter. They join registries. They learn a new language and may travel long distances to find physicians with expertise and interdisciplinary care. They start foundations and form virtual biotech companies. They become caregivers, caretakers, pseudo scientists and doctors, investors and partners. They educate family, extended family, school, community and every physician they will ever meet. They learn a new language, drive regulatory science and healthcare policy. They navigate systems and actively campaign for change. They are aggressive, fearless and effective. They have one single goal – TIME.

Objectives
1. Discuss trajectory of a pediatric rare disease diagnosis
2. Identify opportunities and time points for intervention, support, engagement
3. Discuss the ecosystem of rare diseases and opportunities for partnership between healthcare professionals, researchers, parents/family members and the biopharmaceutical industry

From concept to clinic
Presenter: Maria Grazia Roncarolo
Time: 17:15 - 18:15

Abstract
Investigators developing technologies in an academic setting need to have the tools to evaluate the options that are available to them, when to utilize academic resources, and when to seek other options. This session will examine the TM itinerary in relation to the respective roles of academia, IP, patents and technology transfer.

Objectives
1. Explore the pathway of IP development within an institution
2. Discuss the benefits and detriments of technology transfer
3. Discuss the options, obligations, and strategies of the investigator
Monday, April 4th cont.

Keynote Encounter I
“Patients --- At the Heart of Innovation in Health Care”
Presenter: John (Jack) Lewin
Time: 18:15 - 19:15

Abstract
I have enjoyed an eclectic, professionally exciting, and personally fulfilling career in medicine, health care, and public policy. It has been a pleasure to have practiced medicine in various settings and in diverse financial and healthy delivery environments— including solo practice, academic practice, group practice, hospital practice and government practice. It was also enlightening to have managed a hospital system, and to have founded and implemented two very different health insurance programs. Having been engaged in several health care business start-ups allowed better understanding of the process of innovation in health care. It was also exciting to have played a central role in the creation and implementation of the National Cardiovascular Data Registries (NCDR) as CEO of the American College of Cardiology. The NCDR has enabled measurement and improvement of cardiovascular (CV) outcomes across virtually all of the major hospitals in the US, and has facilitated the robust exchange of CV clinical data for research purposes nationally and internationally. Later on, directly overseeing preclinical and clinical CV research through the Cardiovascular Research Foundation provided insights into new approaches to clinical trials design, and offered opportunities to work closely with industry and regulatory agencies in the research sector. And having been centrally engaged in public health and in public policy during the past 35 years has given me the opportunity to better understand health care financing, epidemiology, and population based health improvement opportunities. It is amazing and gratifying that a career in medicine, health sciences, and public policy could provide so many choices, experiences, and insights. A strong conviction that the profession of medicine -- in addition to offering the powerful experience of direct patient care -- is greatly enriched through the parallel engagement in teaching and research, has contributed in my circumstance to a fulfilling and meaningful personal career, and to fostering a passion for continuous learning, innovation, and personal growth. Career changing opportunities abound in this emerging health care and medical science environment; but it is important to understand as well that the changes ahead will transform the role of the patient as much as the clinician.

The rapid digital transformation of health care is dramatically affecting clinical medicine and research, as well as promoting greater patient engagement in personal care and health. Genetics and genomics are allowing for the increased personalization of diagnostic and therapeutic medicine. Research in today’s rapidly changing digital and information-driven health care environment affords new tools and opportunities that facilitate both the acceleration of scientific progress and the more rapid translation of that ever-evolving body of knowledge to the point of care—to the patient. As a result, a whole new frontier of Phase IV and post-acute care research is being enriched through digital applications of new patient-clinician communication apps, revolutionary biomonitoring tools, interactive social networking systems, the increasing use of Real World Data (RWD), and breathtaking new data and analytics capabilities.

These trends and new opportunities are also changing the ‘culture’ of health care, of innovation, of learning, and of scientific progress. The digital transformation of medicine has the potential to put the patient in the center of health care in unprecedented ways. The once-passive patient is becoming the most important member of the health team. In fact, physicians and other clinicians need to be vigilant to protect against having digital technology further distance them from their patients, and rather insist on using new technologies to strengthen the patient-physician relationship. The inclusion of more women and ethnic diversity into this new culture of care and research is also exciting. And, in the evolving culture of medicine and health sciences, the importance of vision and of adaptive learning in both outcomes improvement and in trial design will become increasingly important. There has certainly never before in history been a more exciting and creative time to participate in health care, in research, and in public health and policy!

Monday Social Program
Wine and Cheese
19:15 - 20:30
Tuesday, April 5th

Coffee
Time: 8:15 - 8:30

Debriefing
Facilitator: Janet P. Hafler
Time: 8:30 - 9:30

Pre-Market Medical Product Development
Presenters: Vicki Seyfert-Margolis
Time: 09:30 - 10:30

Abstract
A background on the latest trends in pre-market product development including biomarkers, diagnostics, devices, drugs and biologics will be discussed with respect to the applied science of product development needed to move more innovative products to the market for patients who need them. Various aspects involved in the science needed to improve product development, from pre-clinical to clinical trials will be described as well as the latest policies under discussion in the United States and Europe.

Objectives
1. Discuss the latest trends, gaps and opportunities in the applied science of product development and evaluation (regulatory science).
2. Describe the stakeholders, priorities and up to date efforts ongoing in regulatory science.
3. Examine the various policy discussions surrounding pre-market product development from discovery to market launch, including funding, regulatory, reimbursement, and other considerations.

Break, 10:30 - 10:45

From Mountains to Molehills: Transforming Basic Research into Leads
Presenter: Paul Krieg
Time: 10:45 - 11:45

Abstract
Basic molecular research generates interesting data and concepts. While conducting successful and insightful experimentation can be rewarding, it is only the gestational step of translational research. In this session, participants will discuss how to evaluate basic research discoveries for leads and give examples of successful basic science studies leading to clinical insights.

Objectives
1. Identify what a lead is and its key elements
2. Identify strategies for evaluating basic molecular science for translational potential
3. Discuss the next steps once a lead is identified
4. Explore the pathway of IP development with in an institution

Group Lunch, 11:45 - 13:00

Unfolding Case Study 1: The Magic Bullet
Written by: Vicki Seyfert-Margolis
Time: 13:00 - 14:00

Abstract
This case examines the full translational tightrope of a targeted therapy, from lead identification to Phase II and III clinical trials. Participants will work in depth with the case in a small group setting over three separate sessions.

Recommended reading will be provided:


Objectives
Through this case, participants will grapple with the development of a therapy intended for a targeted sub-population, and explore the issues arising in the post-market phase. In addition, participants will discuss and determine research and business strategies necessary to “translate” a potential therapeutic, and co-develop its companion biomarker. Parallel concepts of collaboration and team will also be explored.
Tuesday, April 5th cont.

Presenting Preparation and Workshop
Time: 14:00 - 17:00

Abstract
Oral presentation is key to the success of the translational medicine professional, whether the focus of that presentation be research or any other issue related to the translational medicine pathway. Each oral presentation must be crafted to transmit the message in the context of the particular audience. This workshop is designed to support the development of oral presentation skills. Participants will be given a 5 minutes presentation. Peers and faculty will critique the presentation and the presenter will self-evaluate. This the first of a 2-part workshop. While the 2nd workshop (3 days after this workshop) will focus on presentation of a topic outside of the strict boundaries of one’s research, this presentation may focus on one’s personal research or, consistent with the focus of Part II, may focus on an issue related to the translational medicine pathway that you seek to bring to an institutional leader in order to generate a change that will enhance translational medicine.

Objectives
1. Evaluate the best methods for delivering a message
2. Explore strengths and areas of improvement in your personal presentation style
3. Develop presentation/communication skills

Speed Dating I
Time: 17:00 - 18:30

Abstract and Objectives
“Speed dating” provides the opportunity for participants to have a series of one-on-one discussions with individual faculty for 10 minutes each. Topics are the participant’s choice. Please consult the faculty biographies at the end of this program prior to completing the signup sheet, which will be prominently displayed and made available from Sunday.

Effective presenting format

A. Start with a brief statement of the goal to be addressed in your presentation and indicate who you consider to be the target audience.

B. Present for up to five minutes. Your colleagues will participate as the audience and the presentation will be videotaped.

C. 1) You, the presenter, will then view the videotape on your own and, as it plays and for a short time after, develop a list of strengths and suggestions for personal improvement.
   2) While the presenter views the tape, the “audience” of colleagues discusses the strengths of the presentation and suggestions for improvement. Suggestions should
      - Deal with behavior, not with the person.
      - Focus on strengths as much as possible.

D. The presenter and the audience reconvene, each providing feedback on strengths and suggestions. The purpose of this discussion is to:
   - allow for self-reflection on the part of the presenter and feedback in the context of suggestions for future teaching.
   - define and authenticate issues in teaching.
   - provide an occasion for others to help if appropriate.

You will present for up to 5 min.
(and be videotaped)

Review your video on your own (5 min.)

You return to group comment on your review receive feedback (5 min.)

Group discusses and critiques the presentation

The Presentation Workshop
Observation Guide

**Process**

1. How does the presentation begin?
   - How does the presenter capture attention and promote curiosity?
   - How is the overview presented?

2. Is the information presented in a well organized manner?

3. Presentation: Is the delivery paced to the audience’s capacity to follow?
   - Does the presenter avoid reading notes?
   - Does the presenter show any distracting mannerisms?
   - Did the presentation start and end on time?

4. How does the presenter promote active participation? Does he/she
   - use movement?
   - make eye contact with the audience?
   - use aids?
   - ask questions that prompt reflection or response?
   - use buzz groups, voting or brainstorming?
   - problem solve?

5. How does the presentation conclude?
   - Is there a review?
   - Are there follow-up tasks?
   - Is there an evaluation (the one-minute paper)?

6. How is learning assessed?

**Content**

1. Is the content accurate?

2. Does the presenter show a relationship between theory and practice?

3. Is the level of the material appropriate to the audience?

4. Was the presentation complete?
Feedback Tips

Definition
The process of giving data back to the participant for the purpose of bringing about change.

Feedback involves responding specifically to an event or occurrence, whether that event be good or bad. Positive and negative feedback should be distinguished from complimenting and criticizing.

Evaluation is an assessment of a learner’s achievement and/or performance.

1. Feedback should be undertaken with the observer and participant working as allies with common goals. Begin by discussing respective expectations.
2. Feedback should be descriptive rather than evaluative.
3. Feedback should deal with specific events, rather than generalizations.
4. Feedback should be well-timed, and expected, in close proximity to the event, but not when — the recipient is postcall or angry about the issue; facts are missing; or both sides of the situation have not been explored.
5. Feedback should be based on first-hand data.
6. Feedback should be focused on behaviors that are amenable to change.
7. Feedback should involve sharing of information, rather than giving advice, leaving the receiver free to decide for themselves in accordance with their own goals and needs.
8. Feedback can be structured to include subjective data, as long as it is clearly labeled as such.
9. Feedback should be checked to insure clear communication by having the receiver try to rephrase the feedback.
10. Feedback should be followed by attention to the consequences of feedback.

Taking the Plunge
1. Be clear about the purpose of the feedback session.
2. Get the receiver’s perspective as to how things are going.
3. The sandwich technique (i.e., good / bad / good) isn’t always reliable.
4. Ask the recipient to offer solutions.
5. Develop solutions to the problem, and a plan to improve the situation.
Wednesday, April 6th

Coffee
Time: 8:15 - 8:30

Debriefing
Facilitator: Janet P. Hafler
Time: 8:30 - 9:15

“When to Throw a painting to a Drowning Man: an introduction on Translational Creativity”
Artists/Facilitators: Anna van Suchtelen and Brian Goeltzenleuchter
Time: 09:15 - 11:30

Abstract
We like to think that artwork operates like a speed bump that sits casually in the street; not only because it seems to enjoy its ordinary status - privileging those who notice it and gently punishing those who don’t - but because the reaction it generates in the people who run across it seems to say a lot about their comfort level with the things that inevitably happen in life. As artists, we conduct events designed to destabilize – to function outside of the socially-prescribed behavior of artwork; we attempt to test propositions without coercing prescribed outcomes. The forms that our work takes include participatory events and environments, scripted and improvised performances, photography and video and olfactory art. As such, we privilege the aesthetic moment over the aesthetic object.

Paintings for Drowning Men: A workshop on translational creativity is a series of participatory art workshops based on the video When to Throw a Painting to a Drowning Man, commissioned by Eureka Institute for Translational Medicine in 2011.

Objectives
Creating a workshop environment in which participants, can indulge in creative “tasks” which may include cooking, drawing, singing, dancing, as well as other participatory forms. The tone of the project shifts between the comical, the philosophical, and the therapeutic. Ultimately, it is a celebration of the transcendent nature of creativity in our daily lives.

Group Lunch, 11:30 - 13:00

Current thinking on clinical trial design/co-development
Presenters: Vicki Seyfert-Margolis
Time: 13:00 - 14:00

Abstract
Predictive markers, toxicology models, and tools to help shape intelligent drug design and diagnostic development will be explored.

Objectives
1. Identify state of art technologies for predicting toxicology and efficacy
2. Discuss use of the above to optimize the development of new therapies
3. Explore principles of intelligent design of drug development

Unfolding Case Study 2 - The Magic Bullet (continued)
Written by: Vicki Seyfert-Margolis
Time: 14:00 - 15:30

Break, 15:30 - 15:45

Introduction of Presentation Workshop II
Facilitator: Norman Rosenblum
Time: 15:45 - 16:15

Abstract
In this session, the objectives of Presentation Workshop II will be reviewed. Building on the skills developed in Presentation Workshop I and the curriculum on the nature of translational medicine, the presenter will may focus on an issue related to the translational medicine pathway that the presenter seeks to bring to an institutional leader in order to generate a change that will enhance translational medicine.

Objective
1. Identify the objective of presentation workshop II.
2. Discuss approaches that the presenter may use to design a presentation for this workshop.

Small Piece, Big Pie
Presenters: Berent Prakken and Sergio Quezada
Time: 16:15 - 17:15

Abstract
This interactive session will discuss the pitfalls of collaborative research in translational medicine. Various partners (academic institutions, industry, regulatory authorities, etc) are implicated when pursuing research in this area.

Objectives
1. Identify differences in approaching collaborative research with different organizations (academia versus industry)
2. Discuss the issue of intellectual property and confidentiality
3. Identify strategies to tackle obstacles in collaborative research

Wednesday Social Program
Wine and Cheese
18:30 - 20:30
Thursday, April 7th

Coffee
Time: 8:15 - 8:30

Debriefing
Facilitator: Janet P. Hafler
Time: 8:30 - 9:00

Modeling diseases and therapies in experimental systems
Presenters: Norman Rosenblum and Uri Tabori
Time: 09:00 - 10:00

Abstract
Animal models are commonly used to model human diseases. But how reliable are these models? How does the researcher decide? Participants will analyze dilemmas researchers can face while working with animal models.

Objectives
1. Discuss when and why to use animal models
2. Examine how to use animal models
3. Explore the differences between animal models and human diseases

Mentoring Session II
Time: 10:00 - 11:30

Abstract and Goals
See session 1 (Sunday) for abstract and Goals.

Group Lunch, 11:30 - 13:00

Science 3.0
Presenter: Frank Miedema
Time: 13:00 - 13:45

Abstract
When people think of a scientist, they often think of someone who has his or her head in the clouds, motivated by an entirely untainted desire for the pursuit of knowledge and truth. In this presentation, Frank Miedema will cast aside these beliefs about scientists as needlessly naive, and instead suggest that we rebuild our idea of the sciences, particularly the life sciences, with today’s economic reality in mind.

Objectives
1. Understand the impact of external forces on Science as it relates to translational Medicine
2. Develop awareness of the way science shapes both economic and social progress in modern society
3. Realize how increasing pressure to solve real-world problems has forced scientists out of the ivory tower and into the corporate world.

Unfolding Case Study 3 - The Magic Bullet (continued)
Written by: Vicki Seyfert-Margolis
Time: 13:45 - 15:15

Personal work time for Presentation Workshop II
Time: 15:15 - 16:45

Abstract
This session provides time for presenters to create the content and format of their presentation to an institutional leader during Presentation Workshop II.

Speed Dating II
Time: 16:45 - 18:15

Abstract and Objectives
“Speed dating II” provides another opportunity for participants to have a series of one-on-one discussions with individual faculty for 10 minutes each. Topics are the participant’s choice. Please consult the faculty biographies at the end of this program prior to completing the signup sheet, which will be available which will be prominently displayed and made available from Sunday.
**Friday, April 8**

**Coffee**  
Time: 8:15 - 8:30

**Debriefing**  
Facilitator: Janet P. Hafler  
Time: 8:30 - 9:00

**Navigating Late-Stage Clinical Development**  
Presenter: Kenneth A. Oye  
Time: 09:00 - 10:00

**Abstract**  
A well-executed translational medicine program will bring a novel therapy through proof-of-concept to beginning Phase 3 trials. Successful navigation of late-stage development requires careful coordination of teams with proficiency in multiple key scientific disciplines as well as regulatory expertise.

**Objectives**  
1. Discuss milestone regulatory interactions that take place in late-stage development.  
2. Identify various ways that biomarkers can aid clinical development.  
3. Identify changes contributing to growing interest in orphan diseases on the part of biotechnology companies and big Pharma.

**Break, 10:00 – 10:15**

**A Stroll in the Valley of Death: Strategies for Developing a Start-up in the Current Climate**  
Presenters: Wainwright Fishburn and Salvatore Albani  
Time: 10:15 - 11:30

**Abstract**  
The "Valley of Death" is a term typically used to describe the vast expanse between an idea and its delivery to patients and the market. The valley is cloaked by the fog of unawareness and swept by the winds of uncertainty. Many dangers lurk in it. We will discuss the various challenges which have to be overcome, including but not limited to funding in the current climate. We will suggest strategies to maximize the chances of success. Our objective is to disperse the fog and provide awareness of the process.

**Objectives**  
1. Identify the elements leading to the formation of a company as a development vehicle for a translational idea  
2. Describe the current funding process as well as funding policies and their impact  
3. Examine the challenges start-ups encounter in developing an idea into a product tangibly benefitting patients

**Group Lunch, 11:30 – 13:00**

**Siracusa**

Some 2,700 years ago, one of the first Greek settlers dubbed this area “Sirako”. This was in reference to the surrounding salt marshes, beautiful areas dense with sensitive and highly specialized vegetation. Its strategic location and saavy inhabitants helped make Siracusa one of the most powerful city-states in all of Magna Grecia. Cicero called it “the most beautiful of them all”. Ruling factions have changed over time, with the Romans, Byzantines, Arabs, Normans and Swabians all fighting for supremacy in the region. Sicily (and Siracusa) has survived each invasion, and absorbed some important influences evident today. For example, May is the opening month of the Greek Theatre, a premier theatrical event in all of Italy. Architecture further infuses the bones of the city, doric and ionic, baroque and roccoco. And art (high and low, old and new) adorns the city-scape and enriches its museums. Siracusa is not buried in its past, however. The city’s heartbeat is strong with the song of the dolce vita; “ragazzi” enjoy the night life sitting at an open-air coffee-shops, or dancing in one of the many clubs that are concentrated in the area between Piazza Archimede, Piazza Duomo, the Aretusa Fountain and the Alfeo Promenade.
Friday, April 8th cont.

**Communication and Publication**
Presenters: Andrew Marshall and David Hafler  
Time: 13:00 - 14:00

**Abstract**
Publication in a peer-reviewed journal is almost an automatic requirement for a researcher to be able to move a concept into more advanced stages of development. The paper has to be written. Where do you start? In this interactive session you will have the opportunity to explore components of publication process such as authorship, selecting a title, writing an abstract, and writing a rebuttal letter. A senior editor and a translational medicine researcher will frame the discussion and provide their perspectives.

**Objectives**
- Discuss how to decide on authorship.
- Discuss the importance of the title of your paper
- Write an effective draft of an abstract.
- Describe what journal editors look for an effective paper.
- Discuss how to write a rebuttal letter.

**Presentation Workshop II**
Facilitators: Patrick Maxwell and Norman Roseblum  
Time: 14:00 - 16:15

**Abstract**
Building on the skills developed in Presentation Workshop I and the curriculum on the nature of translational medicine, the presenter may focus on an issue related to the translational medicine pathway that the presenter seeks to bring to an institutional leader in order to generate a change that will enhance translational medicine.

**Objectives**
1. Develop the best methods to deliver a persuasive method to an institutional leader to generate collaboration towards change.
2. Identify strengths and areas for improvement in your presentation approach.
3. Identify factors and strategies that will allow you to present more effectively to an institutional leader.

**Mentoring Session III**
Time: 17:30 - 18:30

**Abstract and Goals**
See session 1 (Sunday) for abstract and Goals.

---

**Keynote Encounter II**
‘Towards cure or remission of immune-mediated inflammatory disease: innovation at the interface of academia and pharmaceutical industry’.  
Presenter: Paul-Peter Tak  
Time: 16:30 - 17:30

**Abstract**
Immune system dysfunction impacts almost every area of medicine, from inflammation to oncology and infectious disease to vaccine development. It is crucial for academics to work with pharmaceutical industry if they want to discover and develop medicines for patients with immune-mediated inflammatory diseases. It is also critical that pharmaceutical industry works with the right academics in the right scientific areas. It’s a truism to say we can’t expect to be brilliant in every area, but it’s also true to say that if we’re going to develop medicines that really do make a difference, then the science behind those medicines simply has to be innovative and world-class. Therefore, I will discuss our strategy that is focused on the best science, flexible models for collaboration and open innovation.
Saturday, April 9th

Coffee
Time: 8:15 - 8:30

Debriefing
Facilitator: Janet P. Hafler
Time: 8:30 - 9:30

Grant Writing Workshop
Facilitators: Carol Gregorio, PhD, Paul Krieg, PhD and Norm Rosenblum, MD
Time: 09:30 - 11:30

Abstract
Participants will focus on elements of persuasive grant writing using samples of their own grant summary pages as a foundation.

Objectives
1. Explore effect structures (e.g. abstract flow)
2. Examine content for message clarity and delivery
3. Learn self-assessment strategies for written work

Group Lunch, 11:30 – 13:00

Free Afternoon

Saturday Social Program

20:00 closing dinner

After a week of hard work, creativity and fun please join us for an amazing dinner with enticing wines. Dinner will be served at the Borgia del Casale in the historical suite of Regina Lucia.

Sicilian Delicacies

The title for the “Gastronomic Capital” of Italy is certainly a matter for debate. While some would claim it to be in the Northern regions of the country (specifically Bologna), the South is rich with fresh delicacies. As an island, it makes sense that fish would rank among these fine foods. Bluefin tuna is native of Sicilian waters and sought throughout the world, especially Japan. Fishing techniques date back well over a millennium, with some traceable to Arab rule, and others suspected to be vestiges from the Carthaginian period. Tonnarotti (Italian for tuna fisherman), might recommend a simple breaded tuna steak, while others could tout the finer qualities of “purpetti” (tuna croquettes), or “salsiccia di tonno” (tuna sausage), or even tuna stew. However, one cannot live on fish alone (arguably).

Arabic influences transcends savory dishes, and inspires the sweet. Honey, almonds, and sesame seeds are all linked with the Arabic era in Sicily. They are also the main ingredients for sweets in Siracusa. The “giuggiulena” is a perfect example. Giuggiulena is a hard candy made from exactly those three ingredients. Pistachios, ricotta cheese and chocolate also grace many recipes. Consider the “cassata siracusana” with ricotta cheese and chocolate, or perhaps save your calories for authentic and irreproducible Sicilian cannoli. Since we’ll be in Siracusa during the Santa Lucia festival, one might try a “cuccìa”, made with ricotta cheese and candied squash and fruit. Granita (an icy concoction with almond milk) is paradise on a hot summer day.

After all this eating, you might be thirsty. One thing to try (aside from granita) is Nero d’Avola. The origin of the varietal is unknown, and has thus far only been found in Sicily. A sweeter palate will revel in the wine described by Homer and Hesiod: Moscato di Siracusa, which is rumored to be oldest wine in Italy.
Eureka Translational Creativity

In 2011, the time was ripe for the Eureka Institute for Translational Medicine to add art into its program: Eureka Translational Creativity was born. Translational Creativity was developed to complement Eureka's education and community building initiatives.

Anna van Suchtelen and Brian Goeltzenleuchter are internationally respected artists who have a long history of collaboration. Their Eureka workshop When to Throw a Painting to a Drowning Man highlights the false dilemma of considering art and science as binary opposites. Focusing instead on the commonality of innovation, the artists produced curriculum for science innovators who strive to come to terms with the uncertainty that comes with working collaboratively and across disciplinary borders.

The core theme of the workshop is that creativity is not a talent that one either has or does not have: rather, it is a tool that can be activated and deactivated. Through participating in hands-on and often laughter-inducing group activities, students learn when, why, and how creativity can be deployed in their professional lives.
Translational Creativity CV

2011 – Artists-in-Residence: Brian Goeltzenleuchter and Anna van Suchtelen
2012 – Film release: When to Throw a Painting to a Drowning Man
2013 – Artist-in-Residence: Kate Breakey; Artwork: The Syracuse Still Life
2014 – Artists-in-Residence: Brian Goeltzenleuchter and Anna van Suchtelen; Workshop: When to Throw a Painting to a Drowning Man; Artwork: Paintings for Drowning Men Artists’ Multiple
2015 – Artists-in-Residence: Brian Goeltzenleuchter and Anna van Suchtelen; Workshop: When to Throw a Painting to a Drowning Man; Artwork: Paintings for Drowning Men Hardbound Folio

On the film

When to Throw a Painting to a Drowning Man is an artist-made self-help video that shows how creativity can be useful to anyone. The video offers parables and exercises that evoke the structure of a self-help book. It celebrates the transcendent nature of creativity, examining its potential as a skill and tool for problem solving, critical thinking, networking, and team building. (http://vimeo.com/47049893)
Julia started assisting Professor Salvatore Albani to run Eureka Institute from October 2013. Effective from February 2016, she was seconded fully from SingHealth Duke-NUS Pediatrics Academic Clinical Programme (Pediatrics ACP) to run Eureka Institute as an Executive Manager.

This is the third year she is coordinating the Eureka certificate program. Julia has 26 years of vast experience as an administrator and of which, 14 years were in healthcare. Julia joined KK Women’s and Children’s Hospital in the year 2006 and has been involved with setting up numerous of initiatives in the hospital; the Women Psychiatric Service to a department in end 2011, one of the main lead in the Pediatrics ACP and driving its journey towards Academic Medicine, and the initial set up of Professor Albani’s SingHealth Translational Immunology and Inflammation Centre, in 2013.

Julia is also a proud citizen of Singapore “the little-red-dot” and is full of respect for the late Mr Lee Kuan Yew.
FACULTY DISCLOSURES

Nothing to disclose
Salvatore Albani, MD, PhD
Sylvia Brugman, PhD
Roberto Chinello, MBA, BS Economics
Wainwright Fishburn, JD
Patricia Furlong, RN, BS, MS
Brian Goeltzenleuchter, MFA
Carol Gregorio, PhD
Gianfranco Grompone, PhD, Engineer
Janet Hafler, EdD
Paul Krieg, PhD
John (Jack) Lewin, MD
Andrew Marshall, PhD
Frank Miedema, PhD
Kenneth A. Oye, BA, MA, PhD
Daria Pierotti
Maria Grazia Roncarolo, MD
Norm Rosenblum, MD
Vicki Seyfert-Margolis, PhD
Anna van Suchtelen, MA

Disclosures

David Hafler, MD
discloses an affiliation with Bristol-Myers Squibb, EMD Serono, Genzyme, Juno Therapeutics, MedImmune, Mylan Pharmaceuticals, NKT Therapeutics, Novartis Pharmaceuticals, Pfizer, Roche, Teva Neuroscience, Toray Industries, and Vitae Pharmaceuticals as a consultant/Scientific Advisory Board.

Patrick Maxwell, FMedSci,
discloses an affiliation with Reox Plc. as major stock shareholder.

Joris van Montfrans, MD
discloses an affiliation with Baxalta for research funding support.

Berent Prakken, MD, PhD
discloses an affiliation with Dutch Arthritis Foundation, the Center of Therapeutic Target Validation (CTTV) as Scientific Advisory Board member and NWO for grant/research support.

Sergio Quezada, PhD
discloses an affiliation with MERUS, BioNovion-Genmab for grant/research support and consultant to TUSK, MEDiVATioN, MORPHoSiS.

Uri Tabori, MD
discloses an affiliation/relationship with Thor Hypermethycation.
Paul-Peter Tak, MD, PhD, discloses an affiliation as an employee of GSK.

Paul-Peter Tak, MD, PhD
discloses an affiliation as an employee of GSK.
My fundamental research interest is in understanding human immunity and contributing the knowledge to therapeutic and diagnostic advancements. I have developed several innovative approaches in the area of induction and maintenance of immune tolerance in humans, being responsible for the whole translational process from idea to the conclusion of a Phase II clinical trial in autoimmune inflammatory diseases, which have a large impact on society and individuals. I have been responsible for conception and execution of each of the stages of this complex itinerary, which spans a wide and diverse gradient of technologies and challenges.

These include molecular immunology, lead identification and validation, intellectual property, CMC (Chemistry, Manufacturing and Controls), IND (Investigational New Drug filings), trial design, data management and analysis, interfacing with Venture Capital and Pharma, leading complex groups in a multi-center setting, etc. The technology platform has applications in diseases that could benefit from a restoration of immune tolerance. This translational research itinerary has been the original backbone of my career, as witnessed by a rich publication trail (among others Nature Medicine, Lancet, JCI, PNAS, Nature Rheumatology, A&R, ARD, etc) and by approximately 100 patents.

Development of high throughput technology platforms is also part of my scientific career. These platforms aim to provide tools for knowledge-based diagnostic and therapeutic decisions (various papers and patents under review).

In addition, I have developed a technology for the identification and manipulation ex vivo of antigen-specific T cells. This technology, named T cell capture, is based on entirely artificial antigen presenting cells. It has applications in immunotherapy of cancer and treatment of infections in an immunocompromised host (Nature Medicine, JI. Blood, A&R, Haematologica, various patents). Combined, these approaches span both ways across the gradient of Translational Medicine, which is evidence of and underscores my dedication to this field.

In my role as an educator, it has been my privilege to mentor many talented individuals, and to provide the right challenges and learning opportunities to help them grow and advance. I seek to expand this even further by helping to create and nurture the next generation of translational scientists. An important step is cultivating in translational professionals the necessary awareness, knowledge and experience to contribute significantly to the advancement of the field.
FACULTY BIOGRAPHIES

Sylvia Brugman, PhD

"Sylvia Brugman is a senior postdoc at the Cell Biology and Immunology group..."

Sylvia Brugman is a senior postdoc at the Cell Biology and Immunology group, at Wageningen University where she investigates the intestinal mucosal immune system in health and disease. She investigates microbial composition and immune regulation in the zebrafish gut, and has developed a model for zebrafish enterocolitis. Her current research focuses on innate and adaptive immune mechanisms controlling the response towards microbial and dietary antigens in the intestines and respiratory tract. Sylvia is an alumnus of the Eureka Certificate Program for Translational Medicine (2010). From 2013 she is appointed as e-course developer for the Eureka Institute and together with Elevate Health she developed the introductory course.
FACULTY BIOGRAPHIES

Roberto Chinello, Acute Frog Consulting, Managing Partner, MBA, BS Economics

"I am an experienced consultant with over 20 years experience..."

I am an experienced consultant with over 20 years experience, with multiple industry exposure, focused on delivery project, change management and organizational development. My passion is about creating strategic foresight and innovative leadership in business and new venture environments, to help anticipate and evaluate future uncertainty, respond to emerging opportunities, and innovate and transform to exploit them. I strongly believe that "people" is what makes the difference at the end of the game.

Please find me in http://it.linkedin.com/in/robertochinello

Composing music means dealing with silence, the thing that happens 'between' sounds. For me, consulting means dealing with what happens 'between' the parts of the organization, the processes, behaviors and decisions. I have learned to listen and actively use silence to understand that there is always a good reason for what I observe. Listening is what makes change possible in organizations, because when we understand what such organizations are we can work to improve their resources, i.e. the things that an organization knows and knows how to do. Jaco Pastorius, an electric jazz bassist I love, said "Keep your mind open, listen to everything that's being played", and I think of this as I watch my children grow and when I play the bass. I have worked in Europe, the USA and Japan. And I have tried to always keep my ears open.

roberto.chinello@acutefrog.com
FACULTY BIOGRAPHIES

Wainwright Fishburn, JD

"As a recognized life science and digital health thought-leader, Wain is a frequent speaker at programs addressing industry issues..."

Wainwright Fishburn, Jr. is a founding partner of Cooley LLP’s San Diego office, a prominent venture capital attorney, and chair of the firm’s Digital Health group.

As a recognized life science and digital health thought-leader, Wain is a frequent speaker at programs addressing industry issues, including a keynote at the 2014 and 2015 International CES Digital Health Summit, USC’s Body Computing Conference, Impact Forum and the Wireless-Life Sciences Alliance’s Convergence Summit. Wain has also served as Co-Chair of the BIO Digital Health Forum at the BIO International Convention from 2014 – 2016.

As both a founder and as counsel, Wain has worked with venture capital-backed companies across a variety of fields. For example, in the field of genomic medicine, he works with groups that develop and deploy high-performance network technology for genomic research and medicine. He is on the Board of the Critical Path Institute, a public-private partnership created in part by the FDA, dedicated to integrating scientific advances into the development pathway. Mr. Fishburn has been widely recognized as a leading attorney in numerous publications, including among others, his recent recognition by The Daily Journal as one of California’s top attorneys. He was previously named by Nature magazine as being instrumental to the success of San Diego as a biotechnology hub.

As a community leader, Wain is immediate past Chairman of the Sanford-Burnham Institute for Medical Research, one of the nation’s leading independent biomedical research institutes. He recently joined The Executive Committee of the Board of the UCSD Moores Cancer Center where he is afforded a clinical perspective for the application of breakthroughs in genomic medicine and serves as on the organizing committee for the Center for Personalized Cancer Therapy. He is a founding director of both the Corporate Directors Forum and BIOCOM, the largest regional life science association in the world, representing more than 550 member companies and is a member of its Executive Committee.

Wain is a co-founder of seven companies, two of which are public. He has a B.A. from the University of Arizona and completed post-graduate work as a Senior Fellow at the Australian National University. He received his JD degree from the University of California, Hastings College of the Law and served as President of the Hastings Board of Governors.
Pat Furlong, RN, BS, MS

Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy (Duchenne). Their mission is to end Duchenne. They accelerate research, raise their voices in Washington, demand optimal care for all young men, and educate the global community.

Duchenne is the most common fatal, genetic childhood disorder, which affects approximately 1 out of every 3,500 boys each year worldwide. It currently has no cure.

When doctors diagnosed her two sons, Christopher and Patrick, with Duchenne in 1984, Pat didn’t accept “there’s no hope and little help” as an answer. Pat immersed herself in Duchenne, working to understand the pathology of the disorder, the extent of research investment and the mechanisms for optimal care. Her sons lost their battle with Duchenne in their teenage years, but she continues to fight—in their honor and for all families affected by Duchenne.

In 1994, Pat, together with other parents of young men with Duchenne, founded PPMD to change the course of Duchenne and, ultimately, to find a cure. Today, Pat continues to lead the organization and is considered one of the foremost authorities on Duchenne in the world.
Brian Goeltzenleuchter (b. 1976) is an artist based in San Diego, USA. His recent projects investigate the use-value of cultural objects and institutions. In 2001 Goeltzenleuchter received his MFA from the University of California, San Diego. From 2002 - 2008 he was Associate Professor of Art at Central Washington University. He is currently a Research Fellow at the Institute for Public and Urban Affairs at San Diego State University, and Artist-In-Residence at the Institute for Art and Olfaction in Los Angeles. His work has been screened, performed, and exhibited throughout the United States, Canada, Austria, Italy, China, Croatia, and the Netherlands.

Selected projects include: Sillage, Santa Monica Museum of Art (2014); Adaptive Equipment, Lust Gallery, Vienna, Austria (2011); c (pronounced /k/) Wellness Centre, Southern Alberta Art Gallery, Canada (2010); c Boutique, Museum of Contemporary Art, San Diego (2010); Sponge X Sponge, Colorado State University (2007); Institutional Wellbeing, Centrum Beeldende Kunst, The Netherlands (2006); Who's not for sale, Banff Centre, Canada (2006); Unpacking Iraq, International Festival of New Film/New Media Split, Croatia (2004)
Carol C. Gregorio, PhD

"Dr. Gregorio built and currently directs the Molecular Cardiovascular Research Program (MCRP) at the University of Arizona..."

Carol C. Gregorio, PhD, Professor and Department Head of Cellular and Molecular Medicine, Director of Molecular Cardiovascular Research Program and Co-Director of Sarver Heart Center, The University of Arizona

Dr. Gregorio built and currently directs the Molecular Cardiovascular Research Program (MCRP) at the University of Arizona. Researchers in the MCRP are focused on discovering and disseminating knowledge about the underlying biological and molecular mechanisms of heart development, heart function, heart disease and other malfunctions of the cardiovascular system. Their efforts emphasize translational research. A wide variety of interdisciplinary approaches are currently being used to address questions related to cardiovascular and skeletal muscle biology including developmental, physiological, cellular and molecular biology, genetics, bioengineering, biochemistry, proteomics, live-cell imaging, computational biology and bioinformatics. Dr. Gregorio herself runs an active and well-funded research program with a focus broadly summarized as understanding the cellular mechanisms involved in the assembly, regulation and maintenance of contractile proteins in cardiac and skeletal muscle in health and disease. Dr. Gregorio is an active member of several editorial and philanthropic boards, and is the current chair of a National Institutes of Health grant review study section. She received her Doctorate from Roswell Park Cancer Institute in Buffalo, NY with a major in Molecular Immunology, and did her postdoctoral fellowship at the Scripps Research Institute in La Jolla, CA.
After performing a PhD in microbiology working on E. coli DNA replication and homologous recombination (INRA Jouy en Josas, France, 2002) and a postdoc on the early steps of *Shigella flexneri* entry into intestinal epithelial cells (Institut Pasteur, Paris, France 2005), I switched from Academia to Industry (Danone Research 2005-2015) to work on microbiome driven science and innovation in nutrition through commensals, beneficial microbes and probiotics selection and characterization. At Danone I had different positions from science manager to senior “host and microbes” scientist as well as Latin American R&D representative. In 2009 I spent 3 years as Head of Technology Transfer at Institut Pasteur de Montevideo (Uruguay), to valorise research projects and proofs of concept from the newly created Institute from the Pasteur Institute International Network. Since 2015, I moved back to a public-private organization, BIOASTER (based at Pasteur Institute Paris), which performs technology-based research to solve industrial bottlenecks for innovation in microbiology. I am now the head of the microbiota unit, where we set up with my team new collaborative and translational projects in the field of infectious diseases and microbiology, with a deep focus on the role of human microbiomes (gut, skin, lungs…) in health and disease, to provide new products in the market with Pharma and Food partners.

My main research interest is to decipher the mechanisms underlying the cross-talks between gut microbiota and the host to deliver high impact innovation and product solutions to the market. Since 2009 I am also involved as a consultant for science & technology prospective policies and innovation strategies in Latin American countries.

INTERESTS: Microbiome, innovation and biotechnology, team management, technology transfer, public-private partnerships, globalized open innovation, translational research in food and medicine, “cellular microbiology”, probiotics, host and microbes interactions, innate immunity, science strategy and policies in Latin America.
Dr. Hafler is the William S. and Lois Stiles Edgerly Professor and Chairman Department of Neurology and Professor of Immunobiology, Yale School of Medicine, and is the Neurologist-in-Chief of the Yale-New Haven Hospital. He graduated magna cum laude in 1974 from Emory University with combined BS and MSc. degrees in biochemistry, and the University of Miami School of Medicine in 1978. He then completed his internship in internal medicine at Johns Hopkins followed by a neurology residency at Cornell Medical Center-New York Hospital in New York. Dr Hafler was trained in immunology at the Rockefeller University and then at Harvard where he joined the faculty in 1984 and later became the Breakstone Professorship of Neurology at Harvard and was a founding Associated Member of the Board Institute at MIT. In 2009 he move to Yale as the Chair of the Department of Neurology. Dr. Hafler is a clinical scientist with a research interest in the mechanism of multiple sclerosis with over 370 publications in the field of MS, autoimmunity and immunology. He is a co-founder of the International MS Genetic Consortium a group that identified the genes causing MS. Dr Hafler has been elected to membership in the American Society of Clinical Investigation, the Alpha Omega Society, and was a Weaver Scholar of the NMSS. He is a member of the editorial boards for Journal of Clinical Investigation and the Journal of Experimental Medicine, and is co-founder of the Federation of Clinical Investigation and the Journal of Experimental Medicine, and is co-founder of the Federation of Clinical Immunology Societies and leads the NIH Autoimmunity Prevention Center Grant at Yale. Hafler was a Jacob Javits Merit Award Recipient from the NIH and has won many awards including 2010 Dystel Prize for MS research from the American Academy of Neurology.
Janet Hafler is a Professor of Pediatrics and the Associate Dean for Educational Scholarship at Yale University School of Medicine. As the Director of the Teaching and Learning Center, her responsibilities include developing and implementing medical education and teaching and learning programs for faculty members, students, and residents. Over her career, she has nurtured a climate in teaching and learning where faculty and residents have been exposed to the cutting edge literature and ideas in medical education. She has focused on assisting faculty and residents in exploring innovative ways to effectively promote learning in both the classroom and clinical settings.

Promoting, influencing, and nurturing a climate in which physicians, residents, and students can teach — and learn — has been foremost among her career objectives. She has focused on providing an awareness of context for students, residents, and faculty, urging them to be innovative in their many teaching environments and encouraging them to explore ways to understand how they can effectively promote learning in their interactions among themselves.

Dr. Hafler runs an active research program applying qualitative research methods in medical education. She collaborates with and mentors clinicians and faculty on the elements of qualitative research in the field of medical education and medical care. In turn, mentored faculty members have learned to develop and demonstrate the tools necessary to effectively teach and lead others. Dr. Hafler has published over 100 book chapters, curriculum materials, and original articles in medical education and clinical journals. She has served as visiting professor internationally and has been invited to present regularly at regional and national professional meetings.
Paul Krieg, PhD

"Dr. Krieg has many years of experience in molecular, cellular and developmental biology research..."

Professor of Cellular and Molecular Medicine, University of Arizona College of Medicine.

Dr. Krieg carries out basic research investigating development of the cardiovascular system.

Dr. Krieg has many years of experience in molecular, cellular and developmental biology research. His laboratory focuses on development of the heart and blood vessels in the vertebrate embryo using the frog and chicken as model systems. In recent years studies have concentrated on transcriptional regulation of cardiovascular genes and on the signaling pathways regulating the patterning of embryonic blood vessels. Dr Krieg has published a broad range of articles in basic science journals and participates in national and international research meetings. He teaches basic molecular biology and early embryonic development to medical students in the University of Arizona College of Medicine. He has served on consulting boards for several Biotechnology companies in the US and has more than 20 years of experience reviewing grants on US National Institutes of Health grant review committees and other national and international grant review panels.

Dr. Krieg graduated with a PhD in Molecular Biology from the University of Adelaide in Australia and then carried out postdoctoral research at Harvard University. He established and independent research laboratory at the University of Texas at Austin in 1988 and then moved to the University of Arizona in 1999, where he is currently the Allan C. Hudson and Helen Lovaas Endowed Professor of the Sarver Heart Center.
FACULTY BIOGRAPHIES

Jack Lewin, MD

"Jack Lewin, MD is President and Chief Executive Officer of the Cardiovascular Research Foundation (CRF) in Manhattan, New York..."

Jack Lewin, MD is President and Chief Executive Officer of the Cardiovascular Research Foundation (CRF) in Manhattan, New York. CRF is a highly respected global enterprise focused on preclinical science, human clinical trials, and cutting-edge education in the interventional cardiology space. TCT, CRF’s annual flagship scientific symposium, is the world’s premier meeting in the field, drawing 12,000 leading physicians and healthcare professionals from all over the globe. CRF produces over 50 major meetings in interventional cardiology annually worldwide.

Dr. Lewin is an internationally recognized expert in promoting healthy populations and a strong proponent for more efficient and effective healthcare systems to provide quality care for all. He is the former President of the American College of Cardiology in Washington, DC, and a distinguished leader in health care and regulatory policy who has advised two Presidents of the United States.

Prior to ACC, Dr. Lewin was Chief Executive Officer of the 35,000 member California Medical Association for eight years. Earlier he was Hawaii’s Director of Health from 1986 to 1994, over-seeing 6,500 employees, 12 hospitals, and a billion-dollar budget, helping Hawaii achieve near-universal access to health care. Before that, as a Commissioned Officer in the United States Public Health Service, Lewin founded the Navajo Nation Department of Health, serving America’s largest American Indian tribe. Dr. Lewin also currently serves as Chairman of the National Coalition on Health Care.
Andrew Marshall was appointed Chief Editor of Nature Biotechnology in 2000 after joining the journal in 1996. Since that time, the journal’s impact factor has increased from 11.0 to 32.0. As well as frequently speaking about biotechnology research and translation at international meetings while walking in ever-decreasing circles, he also organizes conferences and symposia for the journal. He has more years of experience in scientific publishing than he would care to mention, particularly at a ‘luxury’ journal; previously, he was Editor of Current Opinion in Biotechnology from 1992 to 1996. He has written hundreds of articles and editorials of varying quality and interest and has contributed to the popular media, including The Economist and Popular Science, and for trade publications. In 2003, he launched Nature Biotechnology’s free-access web portal Bioentrepreneur (www.nature.com/bioent) providing practical information and advice on the challenges of starting a biotechnology enterprise. Since 2007, he has been hosting the networking events termed SciCafés in Boston, San Francisco, San Diego, Houston, London and now New York, which showcase rising stars in academia to early-stage investors and industry R&D leaders. He obtained a BSc with Honors and his PhD and postdoctoral experience in molecular biology and microbiology at King’s College London, where has was given the Helen White Prize, likely as a result of a clerical error.
Professor Patrick Maxwell is currently Regius Professor of Physic at the University of Cambridge.

He graduated from Corpus Christi College, Oxford, in 1983 with First Class Honours in Physiological Sciences. Subsequently, he did his clinical training at St Thomas' Hospital where he won the Mead Medal in Medicine and the Cheselden Medal in Surgery. The principal thrust of his research is in transcriptional control of genes by oxygen. He has worked on this for more than twenty years, initially in Oxford and then as Professor of Nephrology at Imperial College before moving to UCL in 2008 as Professor of Medicine and then Dean of Medical Sciences. His research programme has received substantial national and international recognition and has considerable potential for translation into new therapies for patients. In 2003 with three other scientists, he set up ReOx, an Oxford University spin-out company which ultimately aims to develop medicines from these discoveries.

Professor Maxwell is a Fellow of the Royal College of Physicians, Fellow of the Academy of Medical Sciences and a Fellow of Trinity College Cambridge.

The Regius Professor of Physic is Head of the School of Clinical Medicine at the University of Cambridge and Executive Director of Cambridge University Health Partners, the Academic Health Sciences Centre for Cambridge.
Prof. Frank Miedema studied biochemistry at the University of Groningen, specializing in immunology. As Divisional Manager at the Central Laboratory of the Blood Transfusion Service (CLB) he was responsible for such things as education and research, before going on to become Director of Sanquin Research. Miedema was affiliated with the University of Amsterdam as professor of Immunology of AIDS. In 2004 he became head of the Immunology department at UMC Utrecht. As of 2009, Miedema is vice chairman of the Executive Board of the UMC Utrecht and dean of the Medical Faculty of the University Utrecht.

Miedema is a member of various national and international scientific organizations and advisory committees. He has published hundreds of articles in medical journals, including Nature, Science and Lancet, and is one of the initiators of www.scienceintransition.com. The initiators of Science in Transition believe that the scientific system is in need of fundamental reform. Science should be appreciated for the added value it contributes to society and stakeholders in society must participate in decisions regarding the production of knowledge.
Joris M. van Montfrans, MD

"Dr. J. ( Joris ) van Montfrans studied medicine at Leiden University, and wrote his PhD thesis at the VUMC in Amsterdam..."

Dr. J. (Joris) van Montfrans studied medicine at Leiden University, and wrote his PhD thesis at the VUMC in Amsterdam (topic: Risk factors for Down syndrome). In 2000 he started his training as a pediatrician at the Wilhelmina Children’s Hospital (UMC Utrecht), followed by a fellowship in immunology and infectious diseases. From 2008 he is a consultant in pediatric immunology at the same institute. His medical work is diagnosis and treatment of immune deficiencies, and his scientific focus is on genetics and inflammatory complications of this disease entity.
Kenneth A. Oye is Director of the MIT Program on Emerging Technologies (PoET), with a joint appointment in Political Science and the Institute for Data, Systems and Society. Professor Oye is a faculty associate of the MIT Center for Biomedical Innovation and the MIT Synthetic Biology Center.

His work on science and technology policy centers on the regulation of biotechnologies under uncertainty, with articles on:
- adaptive pharmaceuticals licensing, effective data access, and timely generation of evidence on effectiveness in CP&T; and

His books on international relations include *Cooperation under Anarchy, and Economic Discrimination and Political Exchange.*

Professor Oye serves as Director of Policy and Practices in the NSF Synthetic Biology Engineering Research Center (SynBERC) and as a member of the International Risk Governance Council Scientific Advisory Board.

He has served as an invited expert for the President’s Council of Advisors on Science and Technology report on pharmaceuticals innovation, the WHO consultation on Dual Use Research of Concern, the UN Biological Weapons Convention Meeting of Experts, the NRC Board on Global Science and Technology, and the National Science Advisory Board on Biosafety (NSABB).

He has taught at the John F. Kennedy School at Harvard University, the University of California at Davis, Princeton University and Swarthmore College and was a guest scholar at the Brookings Institution.

He holds a BA in Economics and Political Science with Highest Honors from Swarthmore College and a PhD in Political Science with the Chase Dissertation Prize from Harvard University.
I have worked as HR consultant in the last 16 years. As a Clinical Psychologist, I have chosen to work in complex organizations and focus on my passion: the human being, its behaviors and its emotional and cognitive side.

I am absolutely convinced that the biggest and most valuable challenge, particularly during a training session or an individual/team development context, is to help people increasing their awareness about who they are, how they are perceived by others and how they can contribute in the teams and social systems to which they belong.

I have built my experience by collaborating with several consulting companies, often in a multinational environment. I love designing and managing training processes that can help the participants creating moments of discovery and different ways to express their inner self.

Please find me in https://www.linkedin.com/in/daria-pierotti-9b00309

As a mother of two young girls, I strongly believe that the best way to learn is a combination of having fun while staying in a protected environment, where mistakes are allowed and there is always an opportunity to grow and improve.

I learned that rules are necessary because they can contribute to make people feel safe, and that leadership is primarily sharing a vision and recognizing the value that individual differences can bring to the group.

All my personal life as well my professional achievements have been orchestrated as opportunities to grow, expand my mind and find new ways of doing what I love.

daria.pierotti@acutefrog.com
Berent Prakken, MD, PhD

"He is chair of Research and Education of the Wilhelmina Children’s Hospital..."

Berent Prakken (MD, PhD) is a professor of immunology and pediatrics at the Utrecht Medical Center Utrecht, the Netherlands. He is chair of Research and Education of the Wilhelmina Children's Hospital. Berent Prakken heads a translational research lab that focuses on regulation of inflammation and biomarker development in human inflammatory diseases. He and his group received various prestigious national and international awards and grants. The Prakken lab hosted a core facility for the Immune Tolerance Network of the NIH, and is an international expertise centre for the Luminex technology. Prakken serves as an editor and associate editor of several journals including the Annals of Rheumatic Diseases and the European Journal of Immunology, and is a regular reviewer for most major journals in his field. Berent Prakken was among others chair of the standing committee of pediatric rheumatology in EULAR, and member of the PRES council and EULAR executive committee. He is member of the steering committee of UCAN (international federation facilitating biological research in arthritis) and (thanks to a 1 million euro grant from the Dutch Arthritis foundation) set up the first international platform for biological studies in arthritis (UCAN-U, www.ucan-u.org). He is coordinator of EUTRAIN, an EU FP7 Marie Curie Integrated Training Network for translational research in pediatric rheumatology. Berent Prakken’s personal commitment is to collaboration and training & education. Unconventional thinking and crossing traditional boundaries inspire him, just as his close friendship with Salvo Albani and the other board members of Eureka. As co-founder and board member he enjoys the journey on which Eureka is taking them.
Dr. Sergio Quezada is a Professorial Research Fellow and Group Leader at UCL Cancer Institute in London where he heads the Immune Regulation and Tumour Immunotherapy Laboratory. Prior to this, Dr. Quezada worked with Dr. James Allison at Memorial Sloan-Kettering Cancer Center studying the mechanisms governing anti-tumour T-cell immunity, and how these mechanisms can be manipulated for the generation of potent anti-tumour immune responses.

Dr. Quezada’s research interest at UCL focuses in the study of the mechanism of action of anti-CTLA-4, anti-PD-1 and other immune-modulatory antibodies targeting co-inhibitory and co-stimulatory pathways (including ICOS, 4-1BB, OX-40) and used as novel anticancer therapies. His group has particular interest in the evolution of the immune response to cancer, the impact of immune-modulatory antibodies in the fate and function of tumour reactive T cells, and the role that the tumour microenvironment plays in the response and resistance to such therapies.

Dr. Quezada is a Cancer Research UK Career Development fellow and the recipient of a Cancer Research Institute investigator Award.
Maria Grazia Roncarolo, MD, PhD

"Her efforts focus on the translation of scientific discoveries in genetic diseases and regenerative medicine..."

Maria Grazia Roncarolo, MD, is a Professor of Pediatrics and Medicine at Stanford School of Medicine, Chief of the Division of Pediatric Stem Cell Transplantation and Regenerative Medicine, Co-Director of the Bass Center for Childhood Blood Disease and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine.

Her efforts focus on the translation of scientific discoveries in genetic diseases and regenerative medicine into novel patient therapies, including treatments based on stem cells and gene therapy. Dr. Roncarolo, a pediatric immunologist by training, spent her early career in Lyon, France, where she focused on severe inherited metabolic and immune diseases, including severe combined immunodeficiency (SCID), better known as “bubble boy disease”.

Dr. Roncarolo was a key member of the first team to carry out stem cell transplants given before birth to treat these genetic diseases. Dr. Roncarolo then worked at the DNAX Research Institute for Molecular and Cellular Biology in Palo Alto, where she contributed to the discovery of novel cytokines, studying their role in the induction of tolerance and promotion of stem cell growth and differentiation. As director of the Telethon Institute for Cell and Gene Therapy at the San Raffaele Scientific Institute in Milan, Dr. Roncarolo successfully led the first stem cell-based gene therapy trial for SCID patients lacking adenosine deaminase (ADA), a severe life-threatening disorder. The trial, combining gene corrected blood stem cells with low-dose chemotherapy, is now considered the gold standard for gene therapy in inherited immune diseases. She was also the principal investigator in a successful gene therapy trial for Wiskott Aldrich Syndrome.

During her research on inherited immune diseases, Dr. Roncarolo also discovered a new class of T cells, called T regulatory type 1 cells. These cells play a key role in maintaining immune-system homeostasis by preventing autoimmune and inflammatory diseases and helping the immune system tolerate transplanted cells and organs. She recently discovered specific biomarkers for these T regulatory type 1 cells, which will be used to purify the cells for clinical use and for tracking in patients. She was the first to complete a successful clinical trial using T regulatory type 1 cells to prevent severe graft-versus-host disease in leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Dr. Roncarolo has brought many basic-science discoveries from the bench to patients in the field. She holds eight patents, with six more pending, for methods used in novel cell and gene therapies. She has published more than 280 scientific papers along with 22 book chapters, and her publications have been cited over 20,000 times. She is a Member of the Academia Europaea of Sciences and of the Austrian Academy of Sciences.
Dr. Norman Rosenblum is Professor of Pediatrics, Physiology, and Laboratory Medicine and Pathobiology, and Associate Dean, Physician Scientist Training, at the University of Toronto. As Associate Dean, he is Director of the Undergraduate MD/PhD Program and the Postgraduate Clinician Investigator Program, which together consist of over 150 trainees. Dr. Rosenblum is leading reform of the educational pathway for physician scientists at the University of Toronto and is a frequent advisor on clinician scientist career development in Canada and beyond. He served as Associate Chair of Pediatrics (Research), University of Toronto, from 2001-2008 and led the Canadian Child Health Clinician Scientist Program (CCHCSP) from its inception in 2002 to 2012. Dr. Rosenblum is also a Pediatric Nephrologist and Senior Scientist in Developmental and Stem Cell Biology at The Hospital for Sick Children. He holds the Canada Research Chair in Developmental Nephrology (2005-2019). The focus of Dr. Rosenblum’s research is molecular mechanisms that control formation of the normal and malformed mammalian kidney. He is the author of over 100 peer-reviewed papers and chapters on this subject. Dr. Rosenblum is the recipient of the 2004 Aventis Pasteur Research Award, the American Pediatric Society inaugural 2006 Norman J. Siegel New Member Outstanding Science Award, the Society for Pediatric Research 2010 Maureen Andrew Award in Mentoring, and the Kidney Foundation of Canada 2011 Medal for Research Excellence. Dr. Rosenblum is a founding member of the EUREKA Institute for Translational Medicine, a member of the EUREKA Board of Directors, and a teacher in the annual Certificate Course.
Vicki L. Seyfert-Margolis, PhD

"Vicki L. Seyfert-Margolis founded My Own Med in January 2013..."

Vicki L. Seyfert-Margolis founded My Own Med in January 2013, based on over two years of work on a database, web and mobile application platform technology for family based co-management of health.

Prior to this, Dr. Seyfert-Margolis was the Senior Advisor for Science Innovation and Policy in the Office of the Commissioner of the US Food and Drug Administration. Dr. Seyfert-Margolis began her tenure at FDA during the transition of the Obama administration. While at the FDA, she oversaw the development and execution of an agency wide strategic plan for regulatory science. Dr. Seyfert-Margolis worked with President Obama’s Start-Up America and the White House Jobs Council to help shape policies to promote growth within the biotechnology sector of the US economy. She served as the lead FDA representative on the President’s Council of Advisors of Science and Technology (PCAST) study “Propelling Innovation in Drug Discovery, Development and Evaluation”.

Dr. Seyfert-Margolis also oversaw the design and development of both scientific approaches and policies for issues surrounding food safety, including spearheading efforts to develop testing for dispersant and petro-hydrocarbons in seafood following the Deep Water Horizon, mercury in fish guidelines, arsenic in juices and rice, and radiation level detection in foods following the nuclear accident in Fukushima, Japan.

Prior to the FDA, she served as Chief Scientific Officer at the Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, Dr. Seyfert-Margolis oversaw the development of over 20 leading edge assay development and centralized laboratory facilities, bringing them to GLP and CLIA compliance. She designed and implemented biomarker discovery studies for over 25 Phase II clinical trials across a broad array of immunologically mediated diseases including autoimmune disorders, allergy, and solid organ transplantation.

Dr. Seyfert-Margolis was also an Adjunct Associate Professor with the Department of Medicine at the University of California San Francisco. Prior to this, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases at NIH, where she worked to integrate emerging technologies into existing immunology and infectious disease programs.

Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania’s School of Medicine, and her post-doctoral fellowship work at Harvard University and the National Cancer Institute.
Anna van Suchtelen (New York 1961) studied Literature (MA) in Groningen, the Netherlands and Visual Arts at University of California San Diego, USA. Over the years she professionally moved from literary editor to visual artist. Text and narrative play a crucial role in her visual work, which includes installations, audio works and film. Her projects, often context-specific and interactive, explore the senses, memory and time. Her work has been exhibited, performed and screened in the Netherlands, the United States, Canada, Italy, India and Japan.

Selected projects include: ← → (2015), a film diptych with songlines and soap bubbles; 0° (2015), a film triptych with ice cubes; Pioneer Pop (2014) and Pilgrim Kootwijk (2013-12), interactive walks and film reports; Our Airs Conspire, installation with heat, sound and breathing (2013) nominated by K.F. Hein Art Stipendium; I got life!, installation with shower curtain and soundtrack (2011); Lindenduft, installation with memory cupboards and film (2010); Soft Voices, installation with listening glasses and film (2009); Overtocht (Passing), film and performance on a ferry (2009-08).

http://www.annavansuchtelen-eng.kunstinzicht.nl/
Dr Uri Tabori is a staff Oncologist and Clinician Senior Scientist at The Hospital for Sick Children in Toronto, Canada.

He is also a Principle Investigator at The Arthur and Sonia Labatt Brain Tumour Research Centre at The Hospital for Sick Children in Toronto. Dr. Tabori an associate professor at the Departments of Medical Biophysics and Institute of Medical Science, at The University of Toronto, Faculty of Medicine.

Dr Uri Tabori’s research focuses on combining biological and translational research in Pediatric Oncology. Specifically, he is interested in studying mechanisms underlying brain tumor immortality and recurrence in the context of predisposition to cancer.

Dr. Tabori has been the recipient of numerous national/international awards for his outstanding contributions to biomedical research, The Canadian Cancer Society Bernard and Francine Dorval Prize being amongst one of the most recent ones.
Paul-Peter Tak, MD, PhD

"His academic work focused on translational and experimental medicine..."

Paul-Peter Tak received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He has worked as a scientist at the University of California San Diego for two years. He served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) for 12 years. His academic work focused on translational and experimental medicine. In addition to his work in academia he established a biotech company developing intra-articular gene therapy (Arthrogen b.v.). He has published extensively in peer-reviewed scientific journals (H factor 75).

Since 2011 he has been Senior Vice President (SVP) and head of the ImmunolInflammation Therapy Area Unit at GSK. Since 2016 he is Chief Immunology Officer & SVP R&D Pipeline. He is also co-chair of GSK’s Scientific Review Board, member of the Portfolio Investment Board, member of the Bioelectronics Investment Board, member of the Scientific Advisory Board of Index Life VI (Life Sciences Fund), member of the Board of Directors of ViiV Healthcare and member of the Innovation Board Steering Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Elaine Van De Put, PhD, MSPH

"My current fundamental interest is to help accelerate the translation of scientific discoveries that can impact the health status of our community..."

The bulk of my recent administrative career has been dedicated to improving the efficiency of organizational functions and in implementing processes to accelerate research translation. My current fundamental interest is to help accelerate the translation of scientific discoveries that can impact the health status of our community. I am also very interested in fostering high performance by developing powerful and accountable teams where each individual has the opportunity to develop to his/hers professional potential.

I have over twenty years of experience at the C-Suite level for multinational corporations operating in Latin America as well as in Academic Medical Centers in the United States of America. I currently hold the positions of Chief Strategy Officer for the University of Miami Miller School of Medicine and of Chief of Strategic Operations for the University of Miami’s Clinical and Translational Science Institute, a highly complex cooperative agreement between the University and the National Institute of Health (NIH).

More specifically, I have held positions with responsibility for strategic planning, marketing planning, market research, communications, financial planning, budget planning and budget control for companies such as IBM, Coca-Cola and BAT (British American Tobacco). At the University of Miami I have also held positions such as Senior Associate Dean for Administration, Chief Planning Officer, Chief Marketing Officer and Assistant Vice President for Planning and Analysis. My major strengths are analytical thinking, strategy elaboration and team building.

I received my scientific training as an Immunologist at the University of Miami and was involved in basic science research in the field of aging B cell development for several years. I also hold a Bachelor’s degree in Mathematics, a MS in Industrial Engineering with a specialization in Finance and a Masters in Science in Public Health.
Nancy K. Sweitzer, MD, PhD

"Dr. Sweitzer’s research program has focused on the physiology of heart failure with preserved ejection fraction..."

Nancy K. Sweitzer, MD, PhD, is Director of the University of Arizona Sarver Heart Center, professor of medicine and Chief of the Division of Cardiology in the UA College of Medicine - Tucson. She is a board-certified advanced heart failure and transplant cardiologist and clinical researcher, specializing in heart failure, mechanical circulatory support and heart transplant patient clinical care and research.

Dr. Sweitzer’s research program has focused on the physiology of heart failure with preserved ejection fraction, with attention on decreased systolic reserve and vascular stiffening as important potential disease pathophysiologies. Nationally recognized for her leadership and experience in clinical trials, Dr. Sweitzer has led and collaborated on studies sponsored by the National Institutes of Health, foundation, industry and academic sponsors. She has served on numerous NIH committees and currently serves as a member of the Clinical and Integrative Cardiovascular Science Study Section and the American Heart Association’s Cardiac Biology and Regulation Committee.

Dr. Sweitzer joined the University of Arizona in 2014 after 12 years spent at the University of Wisconsin. At the Sarver Heart Center, she has established a robust clinical research program, focused on delivering efficient, effective clinical research services of the highest quality, with a focus on enrollment goals and regulatory compliance. The program administers numerous translational and clinical projects with a portfolio of Phase 2 and 3 trials reaching hundreds of patients each year. Dr. Sweitzer was recently awarded an American Heart Association Cardiovascular Genome-Phenome Study (CVGPS) Discovery Grant for her research project titled, “Large-Scale Discovery of Mechanistic and Predictive Biomarkers in Phenotypically Distinct Groups of Patients with Heart Failure and Preserved Ejection Fraction.”

Dr. Sweitzer is active in many national societies, including the American Heart Association, The American College of Cardiology and the Heart Failure Society of America. She was recently appointed to the incoming editorial board of the journal Circulation.
Patrick J. Casey, PhD

"James B. Duke Professor of Pharmacology and Cancer Biology Duke University Medical Center, USA..."

Senior Vice Dean Research
Duke-NUS Medical School, Singapore

James B. Duke Professor of Pharmacology and Cancer Biology
Duke University Medical Center, USA

Patrick J. (Pat) Casey, PhD, is the Senior Vice Dean of Research at the Duke-NUS Medical School and also James B. Duke Professor of Pharmacology and Cancer Biology at Duke University. Dr Casey received his BA degree in Biology and Chemistry in 1978 from Augustana College in S. Dakota, PhD in Biochemistry from Brandeis University in 1986, and did postdoctoral work at the University of Texas Southwestern Medical Center in Dallas. He joined Duke as an Assistant Professor in 1990. A recognized authority in the fields of lipid modifications of proteins and in G protein signaling, Dr Casey has received several awards for his work, including the Established Investigator Award from the American Heart Association in 1992 and the Amgen Award from the American Society of Biochemistry and Molecular Biology in 2000. Dr Casey was the founding Director of the Duke Center for Chemical Biology—an organization of Duke scientists dedicated to research and training in the application of fundamental chemical principles to the study of biology and the basis of disease and therapies. Dr Casey relocated with his family, including his wife and scientific collaborator Mei Wang, MD, PhD, to Singapore in 2005 to spearhead the development of research programmes at the Duke-NUS Medical School. He maintains an active research effort in the area of G protein involvement in cancer metastasis.
Pieter A. Doevendans became a cardiologist in Maastricht (trained by H. Wellens) after his medical training at the Leiden University. In 1993-1994 he had the opportunity to work with Ken Chien at UCSD San Diego where the work on embryonic stem cells started. The work was completed in Maastricht and provided the basis for a thesis on the function of the promoter of the atrial Myosin Light Chain gene. Upon return in the Netherlands he worked with Christine Mummery and Hans Clevers (Hubrecht Laboratory) on both human Embryonic as well as human Cardiac stem cells. In the meantime he remained active as an interventional cardiologist initially in Maastricht, but from 2002 on in Utrecht at the University Medical Center. Here he was appointed full professor in Translational Cardiology in 2004 and head of the department in 2005. The focus of the department of cardiology is on Cardiac Failure, stem cells and genetics. He was funded by various national and international foundations. Thus far (2015) he published more than 600 peer reviewed papers and 10 books. In 2012 he was appointed Chairman and Medical Manager Division Heart and Lungs, University Medical Center Utrecht. He is an active member of the European Society of Cardiology we he performed various tasks and is representing the ESC at the Committee for Advanced Therapies at EMA.

Contact: E p.doevendans@umcutrecht.nl, T +31-88-75 59801
EUREKA Institute

PARTICIPANTS BIOGRAPHIES
PARTICIPANTS BIOGRAPHIES

Ashutosh Agarwal, PhD

Dr. Agarwal is an Assistant Professor of Biomedical Engineering at the University of Miami with secondary appointments in the Department of Pathology, Diabetes Research Institute, and Dr. John T. Macdonald Foundation Biomedical Nanotechnology Institute at the University of Miami (BioNIUM). He received his Bachelors degree from Indian Institute of Technology (IIT) Roorkee and PhD from University of Florida, both in Materials Science and Engineering. In addition, he gathered postdoctoral research experience at Columbia University and at Harvard University. Dr. Agarwal joined the University of Miami as a faculty member in 2014 where he heads the Physiomimetic Microsystems Laboratory. He also serves as an Associate Editor of IEEE Transactions on NanoBioscience. Currently, he directs the Physiomimetic Microsystems Laboratory which is involved in developing accurate in vitro models of human physiology and pathology. His current research projects include building a Heart on a Chip (funded by UM/FIU Collaborative Research Exchange Forum), Lung Cancer on a Chip (funded by BioNIUM research award), and Pancreatic Islet on a Chip (funded by NIH). Upon validation, these technologies will be applied towards testing pharmaceutical agents and therapies, driving and monitoring the differentiation and maturation stem cells, and uncovering mechanisms of human disease.

Leonela Amoasii, PhD

Originally from a small Eastern European country, Moldova, I pursued my undergraduate and graduate studies in France at the Louis Pasteur University in Strasbourg. For my doctoral studies I joined the laboratory of Dr. Jocelyn Laporte at the “Institut de Biologie Moleculaire et Cellulaire” (IGBMC), where I worked on myotubular centronuclear myopathy. Studying and living in France for twelve years was a unique experience, both academically and culturally. For my postdoctoral training I moved to Dallas, Texas to work with Dr. Eric Olson, which has given me an amazing opportunity to work in a very productive environment and continue my scientific training. During my first years in the Olson lab, I investigated the roles of Mediator subunits in the regulation of skeletal muscle metabolism. In parallel, due to my expertise with viral delivery systems in muscle, I participated in analyzing delivery of CRISPR/Cas9 genomic editing components to mice via adeno-associated virus to correct the mutation responsible for muscular dystrophy in mice. My long-term career goal is to conduct research as an independent principle investigator at an academic university. My scientific interests are focused on studying gene regulatory networks of muscle function and on applying new gene-editing techniques for correction of muscle diseases.
PARTICIPANTS BIOGRAPHIES

Petra J.J. Baarendse, PhD

Petra (J.J.) Baarendse (1979) is head Research & Education Office of the Division of Pediatric, Wilhelmina Children's Hospital (Utrecht, The Netherlands). From January she is appointed as program leader of Connecting Patients WKZ. After her masters in behavioral biology with an extracurricular specialization in neuroscience (cum laude), she obtained a PhD degree in neuroscience at the Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht. During her PhD, she focused on the role of prefrontal monoamine neurotransmission in social-cognitive development in preclinical models. She spent a year at the Department of Functional Genomics of the Center for Neurogenomics and Cognitive Research (CNCR) Amsterdam. At the CNCR, she worked on in vivo phenotyping and characterizing the contribution of dorsohippocampal NMDA receptors in emotional learning. During her PhD program, she was member of the educational committee of the Graduate School of Neuroscience (2010-2012), member of the PhD representative committee of the Rudolf Magnus Institute of Neuroscience (2008-2012) and representative at the re-accreditation of RMI at the Royal Netherlands Academy of Arts and Sciences (2011). In 2010, she completed training in biobusiness school at Hyphen Projects B.V. After completing her PhD, she worked as a postdoctoral fellow at the Department of Developmental Psychology at the VU University Medical Center Amsterdam. Here, she focused on neurocognitive development and identification of biomarkers of neuropsychiatric disorders in childhood. From 2013 till 2015 she worked as program manager of the child health program, UMC Utrecht. In 2013 she became head Research & Education Office at the Wilhelmina Children's Hospital.

Ann-Marie Chacko, PhD

As an Assistant Professor in the Duke-NUS Programme in Cancer and Stem Cell Biology, and Head of the Duke-NUS Laboratory for Translational and Molecular Imaging (LTMi), Dr. Ann-Marie Chacko’s goals are to advance state-of-the-art small animal imaging platforms for translational applications. A major thrust of LTMi is to develop in vivo molecular imaging technologies to study cancer biology, infectious disease, and brain and immune function, with an Asian disease-centric focus. LTMi offers PET, bioluminescence, and fluorescence imaging modalities, complemented with in vitro/ex vivo services including cell-based assays, biodistribution, and dosimetry. LTMi will soon expand capabilities to include SPECT and ultra-high resolution CT. Dr. Chacko also guides companion radiochemistry and radiolabeling services made available in-house and in nearby GMP facilities. LTMi functions both as a core facility for Duke-NUS researchers and as a hub for emerging imaging research and technology development across Singapore, accessible to the broader research community including other academic institutes and industry groups through contract work and collaborations.

Dr. Chacko has more than 15 years of experience in translational imaging research focused on small molecules, peptides, proteins and nanomaterials. She is the author of 22 scientific publications including original research and review articles, with an additional 20 peer-reviewed publications. Her independent research at Duke-NUS is focused on optimization of drug delivery to the central nervous system, and translation of small molecule diagnostic and therapeutic radiopharmaceuticals in cancer and infectious disease, including Dengue.
PARTICIPANTS BIOGRAPHIES

Valerie Chew, PhD

Dr. Chew graduated with a Bachelor degree in Pharmacy from National University of Singapore (NUS) in 2003. She was then awarded with A*STAR Graduate Scholarship (AGS) and completed her PhD work in B cell signalling pathway from Institute of Molecular and Cell Biology (IMCB), A*STAR Singapore in 2007. Upon completion of her PhD, Dr Chew joined Singapore Immunology Network (SIgN), A*STAR and started her postdoctoral training in tumor immunology. Since Jan 2015, Dr Chew joined SingHealth Translational Immunology and Inflammation Centre (STIIC) to advance her professional career in tumor immunology research. She also holds assistant professor position with Duke-NUS Medical School.

Dr Chew is the key researcher leading the project on understanding the impact of tumor immune microenvironment on clinical outcome in patients with hepatocellular carcinoma (HCC). She led the discovery of an unique 14-immune genes signature in HCC which could accurately predicts patient survival. Based on this discovery, the work has also been extended to testing one of the key immune modulators: toll like receptor-3 (TLR3) in preclinical HCC models. Her current work in STIIC extended to multidimensional deep immunophenotyping and immunomonitoring of HCC microenvironment using several cutting edge multiplex technologies such as Time of Flight Mass Cytometry (CyTOF) and next-generation sequencing (NGS). This powerful approach led to the identification of multiple immune subsets significantly more represented in the tumor tissue that could be of clinical relevance.

Her work has gained recognition with multiple grant awards such as Young Research Collaborative Grant from A*STAR’s Joint Council (JCO) in 2012 and MOH IAF Cat 2 grant in 2015. She is also an invited speaker to International Liver Cancer Association in Paris in 2015 recognising her contribution in the understanding of immune microenvironment in HCC. Several of her research and collaborative work were published in high impact journals including Gut, Journal of the National Cancer Institute, Nature Genetics, and Journal of Hepatology. Having a passion for teaching, she has mentored 5 students in her professional career so far and also lectured in the local universities as a guest lecturer.

Cathleen Ann Collins, MD, PhD

I was raised in Southern California & studied English Literature and Microbiology at UCLA. I attended the Medical Scientist Training Program at UCSF, and in graduate school studied mycobacterial interactions with macrophages. I am currently a fellow in Allergy Immunology at Stanford, after having attended residency in Pediatrics at Stanford. My research interest is in enhancing vaccine efficacy. In my spare time I love to spend time with my husband and two children, go hiking and try new restaurants.
PARTICIPANTS BIOGRAPHIES

Brett Colson, PhD

I recently started my independent muscle research lab in the Department of Cellular and Molecular Medicine at the University of Arizona in September of 2015 as an assistant professor. In our lab, we attach fluorescent probes to cardiac and skeletal muscle proteins in muscle fibers. We then use site-directed spectroscopic techniques such as fluorescence resonance energy transfer (FRET) to study the molecular structures and motions important for contraction. These same high-resolution structure-function assays that we use to determine unknown physiological mechanisms are also used in our lab to pursue discovery of novel drug and small therapies for heart disease and skeletal myopathies. During my postdoctoral training under supervision of Professor Dave Thomas at the University of Minnesota in the Department of Biochemistry and Biophysics, I learned structural biology approaches to studying muscle using fluorescence and magnetic resonance. For my graduate school studies, I learned muscle mechanics to measure kinetics of force generation, trained by my mentor Professor Rick Moss at the University of Wisconsin-Madison in the Department of Physiology. I also learned X-ray diffraction techniques to study muscle ultrastructure from my co-advisor Professor Tom Irving at the Advanced Photon Source in Argonne National Labs. Now, after 12 years of investing the molecular mechanisms of muscle function and dysfunction using basic research approaches, I am eager to transition my focus towards translational research in cardiovascular and muscle diseases.

Tabitha Cooney, MD

I am currently chief Pediatric Hematology/Oncology fellow at Stanford University Lucile Packard Children’s Hospital. I have accepted the position as Pediatric Neuro-Oncology Fellow at Stanford for 2016-2017. Along with principal investigators Dr. Michelle Monje and Dr. Kathy Warren, I am co-investigator for the Phase 1 Trial of Panobinostat in Children with Diffuse Intrinsic Pontine Glioma (DIPG). In addition, I am working on projects related to clinical trial design, survival endpoints, trial enrollment, and survival disparities for children with central nervous system (CNS) tumors. My intention is to become an R01-funded expert in designing local and national Phase 1 and 2 clinical trials for pediatric CNS therapies.
PARTICIPANTS BIOGRAPHIES

Ankit Desai, MD

Ankit Desai, MD, an assistant professor of medicine at the University of Arizona within the College of Medicine - Tucson and Sarver Heart Center, is board certified in internal medicine and cardiology. Dr. Desai is a physician-scientist whose research on cardiovascular disparities in minorities with heart failure and pulmonary hypertension is funded by the National Institutes of Health (NIH) and the American Heart Association. Dr. Desai’s lab integrates novel genome-wide and conventional molecular biology approaches to investigate the underpinnings of pulmonary vascular disease. His lab focus has been on three projects related to the pathogenic mechanisms of pulmonary vascular disease and heart failure:

1. Characterization of the role of ubiquitin pathway and related candidate genes in pulmonary vascular disease
2. Characterization of the role of glycosylation pathway and related candidate genes in pulmonary vascular disease
3. Studying the role of inflammatory pathways in the development of abnormal myocardial electrical properties of sickle cell disease

Previously, Dr. Desai was an assistant professor of clinical medicine at the University of Illinois Hospital & Health Sciences System. He completed medical school at the University of Illinois at Chicago – College of Medicine, internal medicine residency at California Pacific Medical Center in San Francisco, and his cardiology fellowship at the University of Chicago Medical Center.

Dr. Desai serves on several national committees, including the American Heart Association’s Early Career Committee for the Council on Functional Genomics and Translational Biology and the Council on Basic Cardiovascular Sciences, Editorial Board for the journal Pulmonary Circulation, and the American College of Cardiology’s Early Career Professionals Section.

Michael A. Grandner, PhD, MTR, CBSM, FAASM

Dr. Grandner is an Assistant Professor of Psychiatry and Psychology and Director of the Sleep and Health Research Program at the University of Arizona College of Medicine. He is a licensed clinical psychologist and certified in Behavioral Sleep Medicine by the American Board of Sleep Medicine. His research focuses on real-world applications of sleep and health, including studying the downstream cardiometabolic and neurocognitive effects of insufficient sleep, as well as its upstream social, behavioral, and environmental determinants. He has over 75 publications in academic journals and is Associate Editor of the journal Sleep Health. He has won awards for his research from the American Heart Association, Sleep Research Society, American Academy of Sleep Medicine, Society of Behavioral Sleep Medicine, and other organizations. Dr. Grandner serves on and chairs multiple national committees and has served as past President of the Pennsylvania Sleep Society. He is a member of the mental health Task Force of the National Collegiate Athletics Association, where he contributed to the new mental health handbook and best practices guidelines. He also consults with the US Olympic Committee and has worked with both collegiate sports programs and professional sports organizations. Dr. Grandner received his BA in Clinical and Social Sciences in Psychology from the University of Rochester, MS in Clinical Psychology from San Diego State University, PhD in Clinical Psychology from the joint doctoral program at San Diego State University and University of California, San Diego, and a Masters degree in Translational Research from the University of Pennsylvania.
PARTICIPANTS BIOGRAPHIES

Gijs van Haaften, PhD

The last five years I have established my own research group working on the genetics and biology of orphan diseases with a focus on metabolic disorders. In my vision genetics is the crucial connecting factor between patients, clinicians, diagnostics, translational research and basic research. I believe in highly collaborative science where my multidisciplinary background allows me to unite the important stakeholders. I studied (bio)chemistry, obtained a PhD in model system genetics followed by postdoctoral work in human disease biology. I have led several successful collaborations, uniting clinicians, lab specialists and researchers from withing the UMC Utrecht, the Hubrecht Institute and elsewhere, leading to the identification of novel genetic causes of human diseases and last author publications in excellent journals such as Nature Genetics, the New England Journal of Medicine and the American Journal of Human Genetics.

A recent example from my lab is the discovery of the genetic cause of Cantu Syndrome (CS), a syndrome characterised by hypertrichosis, cardiac and vascular anomalies. My lab found de novo missense mutations in ABCC9 in the vast majority of CS patients (Harakalova et al., Nature Genetics, 2012). Rapid implementation of the diagnostic test for CS at the UMC Utrecht ended a diagnostic odyssee for a multitude of patients. ABCC9 is part of an ATP-regulated potassium channel, a known drug target, which made me hypothesise that treatment is possible: Currently I am coordinating a ERARE2 consortium with the aim to treat CS. The consortium unites clinicians and researchers to study CS and at the patient level, in model organisms, in the cell and at the molecular level.

A second example is the discovery of a genetic cause of recurrent ketoacidosis. Here I lead a team of clinicians, lab specialists and researchers from the UMC Utrecht, AMC and abroad to identify inactivating mutations in MCT1 in connection with ketoacidosis (van Hasselt et al., N Engl J Med. 2014). Our discovery improved patient care by allowing a genetic diagnosis, but also provides a paradigm shift in human physiology, where we showed the importance of active transmembrane transport of ketone bodies, in contrast with the current believe of passive transport and MCT1 being mainly a lactate transporter. Currently I am holding a grant from Metakids to study how we can apply our genetic findings to improve patient care.

Louise Hecker, PhD

Dr. Hecker’s broad research background and training has been rooted in regenerative biology, with experience in development, tissue engineering, and mechanisms of injury-repair. Her research team previously identified a novel role for NADPH oxidase-4 (Nox4), an oxidant-generating enzyme, in mediating myofibroblast functions and scar tissue formation (fibrosis), published in Nature Medicine. Since this discovery, her research interests have expanded to include understanding the role of aging/senescence in lung injury-repair responses. Dr. Hecker’s current research interests also encompass translational aspects, including drug discovery for Nox4 and the development of preclinical animal models of acute lung injury and fibrosis.
PARTICIPANTS BIOGRAPHIES

Bert van de Heijning, PhD

My name is Bert van de Heijning (54, Dutch), living together with Bert te Velde in Utrecht, The Netherlands (NL). My main fields of interest and expertise are nutrition and metabolism, in particular digestive physiology and gut biology; by training I am a zoologist and neuroendocrinologist.

Education and professional tenure
After high school I started in 1980 my studies in Biology (MSc) at Wageningen University (NL). Graduation subjects were Zoology and Animal Physiology (Neuroendocrinology), and I obtained my teaching qualification. I spent 6-months as a science trainee in Cambridge (UK). Upon graduation in 1987 I worked as a PhD-student at Utrecht University (NL) and obtained my PhD in 1991 at the Rudolf Magnus Institute for Neurosciences. In 1989 I did a 9-months PhD-traineeship at McGill university in Montreal (Canada).

I had to change from subject and did a 5-yr post-doc in the Gastroenterology dept. of the Utrecht Medical School, followed by a short (2 yr) post-doc in Dairy science in Ede (NL). Hereupon, starting in 1998, I took the position of assistant professor at Wageningen University (NL) in the Human and Animal Physiology group, lecturing Physiology, supervising graduate and PhD-students.

In 2006 I ‘switched to industry’ and became a senior scientist in the Biomedical research dept. of Nutricia. In 2015 I was promoted to principal scientist within Nutricia Research.

Anne Marijn Kramer, MD

I am a NIHR Doctoral Research Fellow undertaking a PhD within the UCL Great Ormond Street Institute of Child Health. In June 2013 I graduated at the University of Amsterdam, where I received my Honours Degree in Medicine. My interest in clinical immunology and haematology grew tremendously after completion of my senior clerkship. I was fascinated by the interplay between the science of haematology and the application of the science to identify and then implement new drug therapies.

As preparation for pursuit of a PhD position, I was offered a position at King’s College as an honorary Research Associate at the Department of Haematological Medicine and was competitively awarded two Dutch scholarships to facilitate the research abroad. This exceptional learning experience contributed to the successful application for a NIHR GOSH/UCL ICH BRC PhD scholarship in translational medicine. My PhD project, which started in April 2014, focusses on cancer immunotherapy in pediatric acute leukaemia, comparing the immunological function of CD19 Chimeric Antigen Receptors with different binding kinetics. This project has resulted in me being named as an inventor on a patent which is currently in submission. Furthermore I have had an active role in scaling up this approach under Good Manufacturing Practise conditions for our upcoming clinical study. I am part of a dynamic group of basic and clinical scientists, who all have a strong interest in translational medicine.

Following my PhD I hope to continue to develop my career towards a specialisation in haematology, performing translational research in addition to clinical training. I have experience in teaching medical students, as well as supervising medical students undertaking research projects as part of their BSc or MSc. Through my Eureka Fellowship, in addition to the skills I hope to acquire personally, I would like to increase the awareness of translational medicine amongst undergraduates and help develop the undergraduate translational medicine curriculum at UCL and the University of Amsterdam.
PARTICIPANTS BIOGRAPHIES

Jae K Lee, PhD

Dr. Jae Lee received his BS from George Washington University in 1997 and his PhD in Neuroscience from Georgetown University in 2005. He completed his dissertation research in Dr. Jean Wrathall’s laboratory investigating plasticity of local reflex circuits after spinal cord injury. He continued his interest in spinal cord injury research as a postdoctoral fellow in Dr. Binhai Zheng’s laboratory at UCSD where he investigated the role of myelin-associated inhibitors and chemorepulsive axon guidance molecules in inhibition of axon regeneration. He started his faculty position at the Miami Project to Cure Paralysis, University of Miami School of Medicine in 2011 where he is currently investigating mechanisms of scar formation after CNS injury.

Naomi Matsuura, PhD, PEng

Naomi Matsuura, PhD, P.Eng., is an Assistant Professor in Medical Imaging with a cross-appointment in Materials Science and Engineering at the University of Toronto. She is the course co-coordinator for the Applied Physics Education Program for the Diagnostic Radiology Residency Program, and a Mentor for the new Masters of Health Science in Translational Research in the Institute of Medical Science at the University of Toronto. As the Director of the Innovation, Translation and Attrition (ITA) Program in Medical Imaging, she leads an initiative to accelerate Medical Imaging innovation in part through establishing interdisciplinary research partnerships between Radiologists, basic scientists and trainees.

Dr. Matsuura leads a research program based on the design of new, translatable contrast agents to guide the personalized treatment of cancer for individual patients. Her group has designed new agents that can be remotely activated using medical imaging sources for cancer imaging and therapy to facilitate the minimally-invasive, image-guided, local and site-specific delivery of cancer therapies to tumours in vivo. Recently, her group has also developed a new biocompatible and clinically translatable nanoscale agent for radiosensitization of hypoxic tumours. Her research program spans across multiple disciplines; from synthetic chemistry to physicochemical characterization, preclinical evaluation in vivo, commercialization, and eventual clinical translation in partnership with clinical collaborators. Awards and recognitions include the John C. Polanyi Prize in Physiology/Medicine and Physics, an NSERC Discovery Accelerator Award, and the Early Researcher Award from the Ontario Ministry of Research and Innovation awarded to outstanding researchers in the early stages of their careers.
Saskia van Mil, PhD

Saskia is associate professor at University Medical Center Utrecht (Netherlands) and her group studies the role of bile acids and metabolites produced by gut bacteria on liver and intestinal diseases such as inflammatory bowel disease (IBD) and non-alcoholic steatohepatitis (NASH). She received her PhD from the University of Utrecht in 2004, on the topic of genetic disorders of pediatric cholestasis (bile acid homeostasis impairment). She received a Marie Curie fellowship from the European Commission to do a postdoc at Imperial College London (UK) with Professors Catherine Williamson and Malcolm Parker to study the role of the bile salt sensor farnesoid X receptor (FXR) in intrahepatic cholestasis of pregnancy. In 2007, she was awarded a competitive NWO-VENI grant (from the Netherlands organization for Scientific Research) and she started as a junior group leader at UMC Utrecht to follow up on her previous research on the roles of bile acids in liver and intestinal disease. Her group uncovered that activation of the bile acid sensor FXR leads to inhibition of intestinal inflammation in different mouse models. With the NWO-VIDI grant, she now studies the molecular mechanisms by which FXR regulates transcription of metabolic and anti-inflammatory genes. Following up from these findings, she is now the project coordinator of the EU FP7-funded FXR-IBD consortium, in which her group, together with the group of Dr Bas Oldenburg (UMCU), TES Pharma (Perugia, Italy) and Enterome Bioscience (Paris, France), aims to develop novel diagnostic and therapeutic approaches for IBD patients (www.fxr-ibd.eu). In addition, in order to lower antibiotics use in farm animals, she is collaborating with DSM to find new solutions to improve gut health in farm animals.

Matthew Ng, MD, PhD

Dr Matthew Ng is a consultant medical oncologist at the National Cancer Centre Singapore with research interest in gastrointestinal cancers and experimental therapeutics. He undertook his oncology training at the Royal Marsden Hospital and UCL Partners (UK) and PhD from the Institute of Cancer Research (London. Currently he is the oncology lead for upper GI cancers and deputy director of the Investigational Medicine Unit. His career track is as a clinical researcher and the aim of the research is to developing novel therapeutic strategies for patients with a subspecialist interest in gastrointestinal cancers. This encompasses performing Phase I trials of first in man compounds, as well as biomarker research to identify molecularly selected subgroups or phenotypes of patients who could benefit from experimental therapy. He also holds National Medical Research Council (Singapore) grants to support this research.
PARTICIPANTS BIOGRAPHIES

Trung Hoang Minh Pham, MD, PhD

Hello! I’m Trung. I’m from Long Beach, California. I’m currently doing my clinical and postdoctoral fellowship in Pediatric Infectious Diseases at the Stanford University Medical Center in Palo Alto, California. I came to Stanford for my residency and fellowship training after completing my combined MD/PhD training at the University of California, San Francisco. For PhD thesis work, I studied the molecular and cellular mechanisms of lymphocyte egress from lymphoid organs. Our work provides insight into the regulations of in vivo lymphocyte trafficking and how these regulations might be potentially manipulated for therapeutic purposes. Currently, my research focus is on host-pathogen interactions during enteric bacterial infections using murine Salmonella infection as a model. I’m interested in understanding the mechanisms by which the immune system identifies and eliminates a certain types of pathogens, which I hope will lead to development of novel immune-modulating therapies for infectious diseases. Outside of science and medicine, my interests include food, cooking, running, swimming, Miyazaki movies, jellyfishes, and architecture. Looking forward to meet you all!

Travis Piester, MD

Dr. Travis Piester is a Fellow Physician in the Stanford University Division of Pediatric Gastroenterology. Dr. Piester was born and raised in Sioux City, Iowa before attending the University of Colorado in Boulder, CO to study Biochemistry. He attended medical school at the University of Iowa, where he graduated with Research Distinction for work in surgical burn care and premature birth genetics. He attended the University of California - Irvine for his pediatric residency before starting his subspecialty training in Gastroenterology, Hepatology, and Nutrition at Stanford University. His current research focus is within the Stanford Children’s IBD Center. His group studies personalized dosing of infliximab, an anti-TNF-α medication, for the treatment of inflammatory bowel disease. As part of a QI initiative to improve outcomes for patients using infliximab, Dr. Piester uses past pharmacokinetic research to determine clinical markers that govern a patient’s drug need. He uses therapeutic drug monitoring to confirm therapeutic dosing and tracks each infliximab patient at each infusion appointment.
Olga Rafikova, MD, PhD

I have over 15 years of research experience and an extensive training in the area of cardiovascular diseases. Specifically, I am studying pulmonary hypertension induced cardiovascular pathology, with a specific focus on molecular mechanisms of uncontrolled vascular cell proliferation, inflammation, oxidative stress, and fibrosis. My education in cardiovascular physiology, complemented by an intensive training in biochemistry and cell biology, provides me with an opportunity to study the molecular mechanisms involved in manifestation of these events on both in vitro and in vivo levels. In particular, I am interested in redox biology and protein post-translational modifications that compromise the function of critical cell enzymes and lead to the development or exacerbation of vascular disease. To study these events, I utilize the protein chemistry and biochemistry, molecular biology and cell culture, animal in vivo and ex vivo approaches to understand, in depth, the particular molecular mechanisms contributing to the disease and their pathophysiological consequences. Besides, I am focused on developing and testing the therapeutic strategies aimed to selectively target the uncovered pathological mechanisms. I have also a long-standing interest in studying gender difference with a focus on the particular molecular mechanisms and signaling pathways leading to manifestation of sexual dimorphism in vascular pathology. Finally, upon joining the Division of Translational and Regenerative Medicine at University of Arizona, I have focused my efforts on translational studies based on the data acquired from patient-oriented research.

Henk Schipper, MD, PhD

Growing up in a large and vibrant family, I was interested in a million things. Even after finishing medical school I have been reluctant to choose a specific career path, and finished a master in philosophy instead. For a while, I planned to be a philosopher and devote my professional life to existential matters. Yet in the end I became pediatrician in training and a passionate medical researcher.

My current research focuses on the consequences of childhood chronic disease. While survival steadily increased over the last decades, many survivors struggle with diabetes and atherosclerotic disease later in life due to long-lasting inflammation and metabolic derangements. Inspired by their courage to live and driven by a passion for translational medicine, my research and clinical work focuses on the etiology and treatment of immunometabolic derangement and its cardiovascular sequelae in children with chronic disease.

Of course there is more to tell. My nonprofessional life accounts for a large part of my motivation and energy. Telling Ties, Jelle and Imke stories before putting them to bed every night are magic moments I would not miss for the world. One day, I hope to finish the traditional Dutch 200km iceskating tour ‘Elfstedentocht’ together with all three of them. Ideally, my wife Emma would join us as well, but she does not like cold at all. Anyway, I could not do it without her.
**PARTICIPANTS BIOGRAPHIES**

**Lina Shehabeh, PhD**

Dr. Shehadeh's laboratory is investigating the molecular mechanisms by which microRNAs regulate heart failure, atherogenesis, and stem cell differentiation. Dr. Shehadeh's expertise in computational biology and data mining allows her to compile masses of genomic datasets to identify candidate genes and microRNAs with potential therapeutic functions. Dr. Shehadeh works on how microRNAs regulate cholesterol synthesis and affect atherosclerotic burden in mouse models of atherosclerosis. Dr. Shehadeh lab is actively engaged in developing a targeted delivery method for microRNAs using aptamer technology.

---

**Tamara Smokvina, PhD**

Dr. Tamara Smokvina is a microbiologist specialized in microbial genetics and probiotic science working in Danone Nutricia Research (R&D of Danone Group) as a senior scientist and project leader in the Life Science Department.

After graduate and post-graduate studies of Biotechnology and Molecular Biology at the University of Zagreb (Croatia) Tamara Smokvina obtained her PhD in 1990 and her HDR (Habilitation for research supervision) in 2012 at University of Paris-Sud (France). Tamara lived and worked in five countries and speaks fluently four languages (French, English, Italian and Croatian).

Tamara’s scientific expertise centers on genetics, genomics and physiology of lactic acid bacteria and bifidobacteria as well as their interaction with host intestinal environment. In her research she focuses on molecular mechanisms of the cross-talk between probiotic bacteria, host cells and gut microbiota in the animal models and in humans.

Tamara’s work consists in designing, building and leading scientific projects and clinical studies in collaborations with the academic laboratories and hospitals, supervising PhD students and post-doctoral fellows and translating scientific achievements into industrial valorization and application. She is often asked by the academia to communicate about her industrial research work to students and post-doctoral fellows. Tamara Smokvina published 24 scientific papers and 10 patents and is a member of the French Society of Microbiology, the Scientific Committee of Doctoral School Paris-Saclay and the Editorial Board of Food, Technology and Biotechnology Journal.
PARTICIPANTS BIOGRAPHIES

**Neal Sondheimer, MD, PhD**

Neal Sondheimer is an Assistant Professor of Pediatrics at the University of Toronto and a Staff Physician in Metabolics at the Hospital for Sick Children. He did his medical and graduate training at The University of Chicago, and studied prion elements with Susan Lindquist for his dissertation. He completed residency in Pediatrics, Genetics and Biochemical Genetics at The Children’s Hospital of Philadelphia. His research interest is in mitochondrial genetics and the expression of the mitochondrial genome.

---

**Rebecca Spencer, BSc, MBChB**

I am a trainee in obstetrics and gynaecology and clinical research fellow, currently in my second year of a PhD in fetal medicine. I graduated from the University of Leeds medical school in the north of England in 2005. During my medical degree I also completed a BSc in clinical sciences and developed an interest in clinical academia. After 2 years of general medical and surgical training I started my obstetrics and gynaecology training in 2007. I completed my membership exams for the Royal College of Obstetricians and Gynaecologists in 2011 and was working as a registrar (UK middle-grade doctor) when I started my time out of training to study for a PhD in 2013. I am currently working at University College London on the EVERREST Project, a European Commission funded project which aims to carry out a phase I/IIa trial of maternal vascular endothelial growth factor gene therapy as a treatment for severe early onset fetal growth restriction (FGR). This is a currently untreatable condition where problems with the blood supply to the womb and across the placenta mean the baby stops growing properly in the middle of pregnancy, leading to stillbirth or the need for very premature delivery. After completing my PhD I hope to combine academic medicine with specialty training in fetal and maternal medicine, eventually becoming an academic fetal medicine consultant with an interest in translational medicine.
PARTICIPANTS BIOGRAPHIES

Charlotte Summers, BScBM, PhD, MRCP, FFICM

Charlotte is the University Lecturer in Intensive Care Medicine at the University of Cambridge. She initially graduated from the University of Southampton, and later undertook a PhD (University of Cambridge) alongside specialist clinical training in Respiratory and Intensive Care Medicine. She was appointed at the UK’s first NIHR Clinical Lecturer in Intensive Care Medicine, and later spent two years as Assistant Professor in Pulmonary and Critical Care Medicine at the University of California, San Francisco, funded by a Fulbright Scholarship and a Welcome Trust Clinician Scientist Fellowship, before returning to Cambridge.

Charlotte’s research interests are the cellular mechanisms of acute pulmonary inflammation, which she addresses using a range of, experimental, translational and early phase clinical studies.

Gavin Tan, MBBS

Gavin is a trained surgical and medical vitreoretinal specialist with a clinical interest in diabetic retinopathy, age-related macular degeneration, intraocular tumours, retinal detachments and pediatric vitreoretinal diseases. In addition, he is actively involved with academic research and Clinical Trials at the Singapore Eye Research Institute (SERI).

Dr Gavin Tan started his career in Ophthalmology at the Singapore National Eye Centre (SNEC). From residency training, where he served as Chief Resident, he went on to complete a two-year Fellowship in Vitreo-Retinal Diseases and Surgery at SNEC in 2014. Under the Singhealth scholarship, Dr Gavin Tan pursued further overseas training in the field of Vitero-Retinal. At the Byer Eye Institute at Stanford University, USA, he mentored with world-renowned Retinal specialists in Pediatric Vitero-Retinal diseases and the use of novel lasers for Retinal diseases. At the Jules Stein Eye Institute at the University of California Los Angeles (UCLA), he honed his clinical expertise in advanced retinal imaging, management of intraocular tumours, and the use of human stem cell derived RPE in the treatment of Retinal diseases.

His main research interest is in diabetic retinopathy under the mentorship of Prof Wong Tien Yin. He is working on projects involving epidemiology; genetics; improving screening modalities; novel imaging of the retina; biomarkers, proteomics and metabolomics; novel retinal laser treatments and improving treatment modalities and strategies in diabetic retinopathy.

His goal is to reduce diabetic visual impairment and blindness by developing and assessing new methods in screening, diagnosis and treatment of diabetic retinopathy with the goal of transforming clinical care and improving patient outcomes.
PARTICIPANTS BIOGRAPHIES

Sander Tas, MD, PhD

Internist-Rheumatologist at the Academic Medical Center (AMC)/University of Amsterdam, The Netherlands. Dr. Tas is a translational scientist with experience in both basic and clinical translational research. He work as an internist-rheumatologist and established an independent research line on the molecular regulation of inflammation, in particular the role of NF-κB signaling and angiogenesis in immune-mediated inflammatory diseases. Projects integrate basic immunological experiments, novel techniques and sampling of multiple tissues. Tools include siRNA and adenoviral vectors to knock-down proteins of interest, but we also generation and investigation of small molecule inhibitors. Ultimate goals include development of new treatment strategies targeting (non-canonical) NF-κB signaling for immune-mediated inflammatory diseases. Research projects are funded both by personal grants (NWO Veni 2008 and ZonMw Clinical Fellowship 2011) and research grants from the Dutch Arthritis Foundation, as well as partnerships with various pharmaceutical companies. Next to these translational studies, Dr. Tas also initiated a clinical research project ("RUBRIC") that aims to ensure optimal (safety, efficacy, medical knowledge, cost effectiveness) medical use of biologics in the treatment of rare, severe and refractory immune-mediated inflammatory diseases.

Emmanuel Thomas, MD, PhD

Emmanuel Thomas MD, PhD is an assistant professor at University of Miami Miller School of Medicine in the Schiff Center for Liver Diseases, the Sylvester Cancer Center and the Department of Cell Biology. Dr. Thomas graduated from medical school at the University of Miami in 2007 (MD) 2005 (PhD). He has research expertise in liver diseases with a focus on viral hepatitis including Hepatitis B and C having obtained pertinent training at the University of North Carolina-Chapel Hill as a Doris Duke Clinical Fellow and the National Institutes of Health. He is an investigator at the Miami Center for AIDS Research (CFAR) and is co-director of the comorbidities and coinfection CFAR scientific area of research (SAR). He is also a CTSI KL2 Scholar and an NIH Loan Repayment Program awardee specifically studying liver disease in HIV/HCV coinfected patients. He is co-director of the Hepatology Diagnostic Laboratory in the Schiff Center for Liver Diseases and also serves on the editorial boards of the Journal of Infectious Diseases and the Journal of Translational Medicine.